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Executive  
summary
Section 1. Context
The overarching aim of the research – to explore the 
prevalence and nature of New Psychoactive Substance 
(hereafter referred to as ‘NPS’) use in Manchester – 
is outlined alongside the key objectives of the research: 
• Gain a clearer understanding of the prevalence and 
nature of NPS use amongst targeted sub-populations 
in Manchester;
• Identify the harms associated with NPS use; 
• Ascertain whether the needs of such sub-populations are 
being met, or not being met, by existing service provision; 
• Identify any staff training and/or knowledge needs; and, 
• Provide recommendations regarding the future 
development and delivery of services in Manchester. 
This section also provides an overview of NPS definitions, key 
legislation (including the recently introduced Psychoactive 
Substance Act 2016) and a review of existing knowledge 
in relation to NPS prevalence, monitoring and motivations 
for use.
Section 2. Methodology
The research team employed a mixed-methods approach 
incorporating analysis of existing JSNA data, targeted 
surveys, interviews, focus groups and observations in city 
centre hot spots and headshops. The research focused on 
the following sub-populations: university students; clubbers; 
the homeless community; offenders released on license 
conditions; and MSM engaged in the chemsex scene. 
Section 3. Findings
The first part of findings section (sections 3.1 to 3.5) is 
organised around the prevalence, nature and motivations 
of use amongst the targeted sub-populations identified in 
section 2. The second half of the findings section (sections 
3.6 to 3.11) discusses the impact of NPS use on a range 
of services (section 3.6), the under reporting of NPS use 
and NPS related incidents (section 3.7), and reasons for 
the lack of engagement with services (section 3.8). Section 
3.9 provides an overview of identified gaps in knowledge 
and training needs. Section 3.10 outlines the need and 
support for a local drugs information system (LDIS). Finally, 
section 3.11 considers the impact of the recently introduced 
Psychoactive Substances Act 2016 on availability and use of 
a range of NPS. 
Students 
Using an online survey, the research targeted Manchester’s 
student population to establish existing NPS prevalence 
and drug trends amongst this sub-population. Of the 134 
students who completed the survey, the main NPS used was 
nitrous oxide with NPS users likely to be poly-drug users.
Clubbers  
Over a third (788) of the 2,139 clubbers surveyed reported 
having ‘ever tried NPS’. The most popular NPS’s 
reported were ketamine and mephedrone. Just over a 
quarter  (27 per cent) of NPS users reported having had a 
negative experience after taking NPS. Almost half 
(47 per cent) were poly-drug users and the concurrent 
‘snorting’ of drugs such as ketamine, cocaine and 
MDMA was identified as needing a targeted harm 
reduction response. 
Chemsex 
This section focuses on the prevalence and service needs 
of men that have sex with men (MSM) who are engaged 
in chemsex. We begin by highlighting competing discourse 
around defining chemsex in a national and local context. 
Despite unequivocal praise for the recent integrated sexual 
health and substance use service – the REACH clinic 
– a number of suggestions for expanding the existing 
service provision are discussed which encompass debates 
about location, opening times, staffing, outreach and the 
integration of mental health and counselling support. The 
training needs of staff are considered. 
Synthetic cannabinoid use amongst   
vulnerable groups 
Observations in popular city centre headshops selling 
NPS found that over 90 percent of sales involved synthetic 
cannabinoids. High rates of prevalence and problematic 
use were established amongst homeless and offender 
populations. Prison was prominent in relation to onset of 
use whilst avoiding MDTs, supported accommodation 
and offender management substance use policies and 
self-medication were main motivations for continued 
use. Synthetic cannabinoids were perceived to be highly 
addictive both psychologically and physically (see section 
3.5.3) with users reporting the rapid build-up of tolerance 
levels. Daily use was common with users reporting a need to 
use to override unpleasant withdrawal symptoms. Numerous 
examples of related harms are identified, including the 
development of mental health issues (see section 3.5.4) 
acquisitive crimes and violence (see section 3.5.6) and deaths 
attributed to use. We highlight the lack of user engagement 
with services and the need for more integrated mental health 
support (see section 3.5.5).
Taking the strain: The impact of NPS use on services 
within Manchester 
The significant impact that NPS use is having on a range 
of services is illustrated. In particular, we demonstrate how 
the sale and use of NPS in the city centre has created a 
significant resourcing issue for the police and the medical 
service. We note how call outs for ambulances have 
increased sharply, as has the burden on A&E departments 
and supported accommodation providers. 
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NPS recording and monitoring
This section highlights that current recording and 
maintenance of routine data on NPS is flawed and 
likely to represent an underestimate of use. The lack of 
robust systems for recording NPS-related incidents was 
widespread among services and even in organisations 
that attempt to keep records their systems were inconsistent 
and ad hoc. 
NPS use and service user engagement
This section explores the reasons why NPS users are not 
accessing the available support on offer. This includes NPS 
users’ stereotypical views of services as a place for injecting 
heroin and crack cocaine users, the location, the lack of 
substitute medication and perceived lack of service provider 
knowledge on how to treat NPS users. The need for more 
bespoke NPS services and interventions are discussed in 
relation to the changing profile of ‘problematic’, dependent 
and injecting users.
Training and knowledge gaps
The research identified a clear need for a revised model of 
training around NPS for staff working in frontline services. 
This section illustrates existing gaps, training needs, and 
the need for clear guidance on best practice. 
Developing a Greater Manchester Local Drug 
Information System (LDIS)
This section evidences a significant demand for a local 
drug information sharing system (LDIS). The Public Health 
England LDIS guidance is introduced, which we argue 
would provide a platform to enable frontline staff to share 
knowledge gained from first-hand experiences and would 
thus help to educate staff on developing ‘good practice’, 
provide a centralised location for information, and for sharing 
up to date information on new substances and ‘bad batches’ 
(see also section 4.1.2). 
Impact of the Psychoactive Substances Act 2016 
The research concludes that the Psychoactive Substance 
Act 2016 will have little impact on availability and usage 
of many types of NPS use reported by the targeted sub-
populations (see sections 3.2 to 3.5). We conclude that the 
main group of NPS users affected are synthetic cannabinoid 
users. The findings report the rapid establishment of a 
street level synthetic cannabinoid market that has led to an 
increase in prices. This, we suggest, will most likely lead 
to more incidents of violence amongst users and crimes 
being committed to fund dependent use (as reported in 
section 3.5.6).
Section 4. Recommendations 
The recommendations centre upon three main themes: 
development of resources, service development and 
future research. 
Development of resources
The findings (see section 3.7 in particular) identified a 
need to increase existing NPS related knowledge amongst 
specialist substance use providers and a wide range of other 
medical and non-medical occupations. We propose three 
main ways of achieving this.
• The development of bespoke information sheets – brief 
(i.e. 2 pages) – targeted at specific services and tailored 
around the types of NPS use they are likely to encounter 
e.g. synthetic cannabinoids. 
• NPS awareness training and continuous professional 
development (CPDs) that moves towards more practical 
and tailored training. 
• The creation of a Local Drug Information System (LDIS), a 
virtual resource that facilitates the sharing of information 
and good practice across services. 
Service Development 
Section 4.2 suggests the need for more innovation in the 
development of intervention responses and marketing 
approaches that encourage service engagement. This 
includes outreach and ‘pop-up’ services (e.g. pop-up needle 
exchanges), and a move away from traditional responses, 
operating hours and locations to better accommodate newly 
emerging user groups. We outline the need for guidance on 
good practice (section 4.2.2), cultural competence (4.2.2.), 
treatment pathways (4.2.3), integrated service delivery 
(4.2.4) and a NPS user engagement strategy (4.2.5). 
Future Research Agenda
The need to improve existing knowledge recording systems 
such as treatment data, emergency services, A&E and other 
medical and non-medical services is noted (section 4.3.1). 
This should include ongoing monitoring of the impact of 
the Psychoactive Substance Act 2016 (section 4.3.4) and 
the establishment of an annual emerging drug trends and 
drug markets survey (see section 4.3.5). The relationships 
between NPS use and recovery journeys (see section 4.3.2), 
NPS use and crime and disorder, and the impact of NPS use 
on offender management  are identified as areas of priority 
for future research. 
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1.1 Aims and objectives
This research was commissioned by Manchester City 
Council’s Community Safety Partnership Board. The 
overarching aim of the research was explore the prevalence 
and nature of New Psychoactive Substance (hereafter 
referred to as ‘NPS’) use in Manchester. The key objectives 
of the research were to: 
• Gain a clearer understanding of the prevalence and 
nature of NPS use amongst targeted sub-populations 
in Manchester;
• Identify the harms associated with NPS use; 
• Ascertain whether the needs of such sub-populations are 
being met, or not being met, by existing service provision; 
• Identify any staff training and/or knowledge needs; and, 
• Provide recommendations regarding the future 
development and delivery of services in Manchester. 
1.2 Defining NPS 
Although the term NPS is now widely used, there remains 
some debate as to whether we should be referring to ‘New’ 
or ‘Novel’ Psychoactive Substances. This is because a 
number of the most widely used substances (for example, 
nitrous oxide or mephedrone) were synthesised many 
years ago and as such are not new, they are simply 
being used in novel ways. Nevertheless, in the context of 
this report, we use the most widely used term which is 
‘New Psychoactive Substances’. The Home Office defined 
NPS as:
Psychoactive drugs, newly available in the UK, which are 
not prohibited by the United Nations Drugs Conventions 
but which may pose a public health threat comparable 
to that posed by substances listed in these conventions. 
(Home Office, 2014)
In the UK, NPS are often referred to as ‘legal highs’ within 
the media. This is due to the fact that these substances 
– which have often been specifically designed to mimic 
the psychoactive effects of controlled substances – have 
not been classed as illegal under the Misuse of Drugs Act 
1971. By marketing themselves as ‘research chemicals’ or 
‘plant foods’, and labelling themselves as ‘not for human 
consumption’, NPS can evade prosecution under the 1971 
Act. However, there is now a growing consensus that the 
discourse needs to move away from the term ‘legal’ as many 
users, especially young people, equate ‘legal’ with ‘safe’. 
1.3 NPS legislation 
NPS first started becoming popular in the UK 
around 2008/2009. Synthetic stimulants such as BZP 
(benzylpiperazine) and mephedrone, and synthetic 
cannabinoids such as ‘Spice’ (JWH-018), were among the 
first NPS to gain popularity. Ever since then, there have 
been concerns around the harms caused by NPS, with a 
number of deaths connected to them. These concerns have 
not only given rise to campaign groups such as the Angelus 
Foundation1, but they have also led to a raft of legislative 
changes. For example, synthetic cannabinoids including 
‘Spice’, mephedrone and other cathinones, and GBL 
(gammabutyrolactone) are now included under the Misuse of 
Drugs Act 1971. The establishment of Temporary Class Drug 
Orders (TCDOs) in 2012 also led to raft of other NPS, such as 
NBOMe (25I-NBOMe) and Benzofuran (5- and 6-APB), being 
banned under the 1971 Act. 
Despite these legislative changes it has been difficult to 
control the use of NPS. This has led to the introduction of 
what has been perceived as a ‘blanket ban’ of NPS in the 
form of the Psychoactive Substances Act 2016, introduced 
at the end of the data collection phase of this research on 
May 26th 2016. The 2016 Act proscribes the importation, 
production and supply of psychoactive substances 
(although alcohol, tobacco, caffeine and most medicines 
are exempt). Up until the 2016 Act, NPS were widely 
available via online sellers, headshops, newsagents and 
other retailers, alongside the traditional street-level drug 
market. With the main intention of the 2016 Act being 
to facilitate the closure of shops and websites that trade 
in NPS, it is envisaged it will reduce availability of NPS. 
The potential impact of the 2016 Act on NPS availability 
and use in Manchester constitutes a central theme of 
the research and is discussed in detail later in the report (see 
section 3.11).
Alongside these legislative developments, a range of 
national and international guidance documents and reports 
have been developed by: Public Health England (Public 
Health England); the Advisory Council on the Misuse of 
Drugs (ACMD); the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA); and the United Nations 
Office on Drugs and Crime (UNODC). Most notably in the 
context of this report, these have included the: ‘Clinical 
Management of Acute and Chronic Harms of Club Drugs 
and Novel Psychoactive Substances’ (NEPTUNE, 2015); 
early warning advice (see, for example, the UNODC’s Early 
Warning Advisory, the EMCDDA’s Early Warning System, 
and the Home Office’s Forensic Early Warning System 
Annual Reports); and recent Public Health England guidance 
on how to establish local drugs information systems (LDIS) 
(see Public Health England, 2016). We draw on these key 
sources at various stages throughout the report, together 
with national and international survey data and academic 
studies researching NPS prevalence, motivations for use, 
and perceived harms. 
1.4 NPS monitoring and categorisation 
International monitoring systems inform us that NPS are 
being produced at an unprecedented rate. Manufacturers are 
continually developing new chemicals to replace those that 
become banned, changing chemical structures to stay one 
step ahead of legislation. By way of example, the EMCDDA 
formally identified 101 new NPS in 2014 (EMCDDA, 2015). 
A year later, a further 75 new substances were identified 
(21 synthetic cannabinoids, 20 synthetic cathinones, and 
phenethylamines) (EMCDDA, 2016). As of December 2015, 
643 NPS were registered in the UNODC Early Warning 
Advisory on NPS (UNODC, 2016). 
While there is no agreed official list of substances that  
are categorised as NPS, they are most commonly grouped 
into five broad categories: 
• Stimulants: such as piperazines (e.g. BZP), cathinones 
(e.g. mephedrone), benzofurans and methiopropamine; 
• Sedatives: such as benzodiazepine analogues 
(e.g. etizolam) and new synthetic opioids; 
• Hallucinogens: such as NBOMes and alpha-
methyltryptamine; 
• Dissociatives: such as methoxetamine; and, 
• Synthetic cannabinoids: such as 5FAKB-48. 
However, it is worth noting that some recent NPS do not fall 
into these categories. For example, in 2015, 21 substances 
were reported for the first time that (structurally) did not 
fit within any of the above mentioned groups (UNODC, 
2016). In the UK alone, the Home Office’s Forensic Early 
Warning System (FEWS) – which produces annual reports 
on the content of NPS that are purchased through headshops 
and online sellers, together with samples confiscated from 
clubbers, festivalgoers and prisoners – identified four new 
NPS (FEWS, 2015). With so many NPS available, a key aim 
of the research has been to establish the types of NPS that 
are used in Manchester, and how use may or may not differ 
amongst various sub-populations in the city. 
1.5 NPS prevalence 
Prior to outlining the research methodology and findings, it 
is useful to begin with a brief review of contemporary British 
and international research regarding NPS consumption and 
the motivations for use. In doing so, we begin to highlight 
some of the key knowledge gaps  that exist in relation to 
the specific sub-populations that we focus on in this report. 
Both the UN and EU early warning systems have consistently 
found that synthetic cannabinoids comprise the largest group 
of NPS, representing about a third of all NPS identified 
(EMCDDA, 2015; UNODC, 2015). However, the identification 
and monitoring of a substance does not necessary map on to 
consumption rates. The main survey of substance use is the 
Crime Survey of England and Wales (CSEW). It estimates the 
prevalence of NPS (when compared to traditional drugs) as 
very low, with only 2.8 per cent of 16 to 24 year olds, and 0.9 
per cent of adults aged 16 to 59 having taken an NPS in the 
last year (CSEW, 2015). This equates to around 175,000 young 
adults aged 16 to 24 (128,000 male and 47,000 females). In 
contrast to these findings, the 2014 Eurobarometer survey of 
young people (aged 15 to 24), conducted across the European 
Union, found higher proportions of young people in the UK 
reporting past year use of at least one NPS, at 10 per cent 
(European Commission, 2014).
In addition to differences in estimates of usage, significant 
variations are also apparent when different types of NPS 
consumption are analysed. For example, in the 2014/15 survey 
(CSEW, 2015), past year use of nitrous oxide was reported 
by 7.6 per cent of 16 to 24 year olds, making it the second 
most used substance after cannabis. In contrast, the most 
commonly found group of NPS by customs officers or early 
warning systems – synthetic cannabinoids – was reportedly 
used by only 0.2 per cent of 16 to 24 year olds, and only 0.1 
per cent of adults aged 16 to 59 (CSEW, 2013). This very low 
reported rate of use of synthetic cannabinoids resulted in them 
being omitted from subsequent annual CSEW surveys. This 
type of nationally representative household survey is likely to 
under-estimate prevalence because it excludes a number of 
sub-populations who are traditionally known to have much 
higher than average rates of substance use, such as students 
living away from home, the homeless community and those 
in temporary or supported accommodation, and the prison 
population. As we go on to outline in section 3, reported use 
of NPS (such as nitrous oxide and synthetic cannabinoids) 
amongst some of these sub-populations is considerably higher 
than that found in the general population. 
The need to drill down into NPS use amongst specific 
sub-populations has recently been highlighted in the annual 
report of HM Inspectorate of Prisons (HMIP, 2014). This 
report unequivocally claimed that synthetic cannabinoids 
had become entrenched in the prison system in England and 
Wales. ‘Spice’, as it is generically referred to, has established 
itself as the ‘drug of choice’ for prisoners, with recent 
estimates of prevalence suggesting that between sixty to 
ninety per cent of the prison population are users (Centre for 
Social Justice, 2015; HMIP, 2015; Ralphs et al., 2016; RAPT, 
2015). Furthermore, it has been argued that many of these 
are regular users (Baker, 2015; Centre for Social Justice, 
2015; Ralphs et al., 2016). These levels of consumption are 
remarkable given that, at the time of writing, there are over 
85,000 people residing in prisons in England and Wales 
(Howard League for Penal Reform, 2016). 
The CSEW (2015) has observed much higher levels of drug 
use amongst those people who report frequently going to 
pubs, bars and nightclubs, and among different sexualities. 
The use of any Class A drugs in the last year was around 10 
times higher among those who visited a nightclub at least 
four times in the past month (19.2 per cent) compared with 
those who had not visited a nightclub in the past month 
(1.8 per cent). It also found that overall, LGBT adults were 
significantly more likely than heterosexual adults to have 
taken illicit drugs in the last year (28.4 per cent compared to 
8.1 per cent). Gay and bisexual men were more likely (33 per 
cent) to have used drugs in the last year than heterosexual 
men (11 per cent). Drilling down further to look at types 
of drugs used, reported use of stimulants was around five 
times higher among gay and bisexual men than among 
heterosexual men, with methamphetamine use around 15 
times higher. The CSEW and other targeted surveys also 
report evidence that the use of GHB/GBL is also concentrated 
among gay and bisexual men (see CSEW, 2015; Halkitis & 
Palamar, 2006; Miotto et al., 2001).
1.6 Motivations for use
In addition to establishing the prevalence of NPS use 
in Manchester, the research also aimed to ascertain the 
motivations for use. In a recent review of international 
research, NEPTUNE (2015) pinpoint the main motivations 
among recreational drug users for the consumption of all 
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types of NPS as: price; purity; availability; desired effects; 
and legal status2 (see also Home Office, 2014). In a British 
context, the emergence of NPS use, particularly synthetic 
cathinones such as mephedrone, has been attributed to a 
growing disillusionment with the quality of illegal drugs 
throughout the 2000s (Carhart-Harris et al., 2011; Measham 
et al., 2010; Newcombe, 2009; Van Hout & Brennan, 2011). 
Legality (Measham et al., 2010); curiosity (Newcombe, 2009; 
Norman et al., 2014); preferred effects (Carhart-Harris et al., 
2011; Newcombe, 2009; Van Hout & Brennan, 2011; Winstock 
et al., 2010); affordability, especially for young people with 
low incomes (Carhart-Harris et al., 2011; Measham et al. 
2011b; Winstock et al., 2010); and boredom (Newcombe, 
2009) have also been identified as motivations for use. 
However, these motivations, generically attributed to all 
types of NPS, are often established in studies dominated 
by synthetic cathinones – most notably mephedrone – and 
conducted with recreational rather than a range of users, 
including problematic or dependent users. 
An often under-explored motivation for the consumption of 
NPS, particularly for those subject to regular mandatory drug 
tests (MDTs) and wishing to avoid sanctions, is their non-
detectable nature (Barratt et al., 2013; Bebarta et al., 2012; 
Perrone et al., 2013). It has been argued this has become a 
key driver for synthetic cannabinoids consumption among 
the UK prison population, as well as their less detectable 
smell when compared to natural cannabis (Home Office, 
2014; Neptune, 2015; Ralphs et al., 2016; RAPt, 2015; Walker, 
2015). The attraction of using a psychoactive substance 
that evades detection will also remain an omnipresent 
motivation for those subject to such tests on release from 
custody (due to offender management license conditions), 
or those working in occupations where drugs tests are 
enforced (such as machine operatives and those working in 
transport industries). Another notable gap in much of the 
existing literature around motivations for NPS use is the 
area of addiction and dependency. As we outline below, 
to investigate this key issue, our research specifically 
focused on sub-populations who are traditionally known to 
have high rates of drug and alcohol dependency, as well as 
complex needs. 
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2.1 Sub-populations
As we noted earlier (see section 1.5), much of the existing 
knowledge on the prevalence of NPS is based on data 
garnered from nationally representative household surveys, 
such as the CSEW. However, as we have already highlighted, 
these sources of data under-represent those very populations 
that have traditionally exhibited higher than average levels 
of substance use, such as university students, the homeless, 
and those in prison. Because of this, rather than attempting 
to undertake a comprehensive general population survey of 
(Greater) Manchester, this piece of research focused instead 
on a number of specific sub-populations within Manchester. 
The choice of sub-populations was informed by, not only 
a review of the existing literature, but also conversations 
with a range of frontline workers in the field. In addition 
to a focus on young adult recreational users of NPS, the 
other populations within which NPS use was identified as 
being particularly prevalent were: the homeless community; 
those in prison; those in supported accommodation; 
and men who have sex with men (MSM) who engage in 
chemsex. As a result, the research focuses on the following 
five sub-populations: 
• university students; 
• clubbers; 
• those engaged in the chemsex scene; 
• those in prison; and, 
• the homeless community. 
2.2 Mixed-methods
The research was conducted over a six-month period 
between January and June 2016. The research team utilised 
a mixed-methods approach incorporating secondary data 
analysis of existing data, alongside primary data collection 
– involving a combination of qualitative and quantitative 
research methods – and analysis. 
2.3 Quantitative methods
In relation to the quantitative elements of the research, 
secondary data analysis was undertaken of 2,139 
questionnaires, collected as part of a recent club drug survey 
in Manchester. In addition, quantitative analysis of primary 
data collected involved: 55 questionnaires completed 
by those currently engaged with the charity Homeless 
Link in Manchester, and 134 online surveys focused on 
NPS use amongst Manchester’s large student population. 
The quantitative analysis was undertaken using 
IBM-SPSS Statistics.
2.4 Qualitative methods
The qualitative element of the research adopted a 
range of methods, including ethnographic observations, 
interviews and focus groups. Ethnographic observations 
were conducted in various settings, including: city-centre 
headshops; homeless drop-in activity and advice centres; 
medical practices; and ‘hot spots’ for NPS use in and around 
the city centre (such as, Piccadilly Gardens, Urbis and 
Bury New Road). The research team also observed: service 
providers dealing with individuals under the influence 
of NPS; members of the public collapsed outside medical 
centres; dealing on the streets; and ambulance services 
being called to local drug services. During these ethnographic 
observations, the research team spoke to NPS users in an 
informal, ad hoc manner, leading to several impromptu focus 
groups and short interviews (some of which were recorded, 
when appropriate) in headshops, outside drop-ins and on 
the street. 
One-to-one interviews and focus groups formed an 
integral part of the research as we sought to uncover 
the opinions of both NPS users and service providers. 
Interviews and focus groups with users primarily focused 
on the motivations for use, as well as experiences of 
using NPS. Furthermore, in order to better inform any new 
and/or existing services on how best to respond to NPS use, 
we primarily focused on speaking to NPS users who were 
not currently accessing treatment services. This allowed us 
to investigate their reasons and motivations for not seeking 
support or engaging with local service provision. In total, we 
conducted 53 interviews with users. Of those interviewed: 
41 were adult users (aged 25 or above); 12 were young 
people  (aged 16 to 24); and the vast majority (48) were 
male. Five focus groups were conducted with NPS users: at 
homeless day centres (n=1); homeless GP surgery drop-ins 
(n=2) and supported housing (n=2). In addition, to gathering 
the perspectives of NPS users, we also interviewed those 
involved in the supply of NPS: in  this instance, one dealer 
and one headshop worker.
In order to highlight any current gaps in knowledge, training 
and monitoring, the research team also conducted 31 
interviews with practitioners and service providers. Given the 
multi-faceted nature of NPS use and the challenges associated 
with it, these interviews encompassed the views and 
experiences of a wide range of professions and occupations, 
including: adult drug and alcohol services; sexual health 
clinics; chemsex services; the LGBT Foundation; needle 
exchange services; offender management (including prison 
and probation); police; PCSOs; commissioning services; 
supported housing providers; approved premises; homeless 
day centres; homeless outreach teams; young people’s 
homeless services; young people’s mental health services; 
young people’s substance use services; GPs and other medical 
practice staff; and A&E consultants and nurses. In total, 
86 interviews were conducted with practitioners and 
service providers, with each interview lasting on 
average between 60 and 90 minutes. All interviews 
were transcribed in full and analysed using NVivo qualitative 
data analysis software.
Findings
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3.1 The prevalence and nature of NPS 
use amongst targeted user groups
Different sub-groups of the overall population often show 
unique patterns across a number of behaviours and 
substance use is no exception (see Abdulrahim et al., 2016). 
As outlined in section 2, the research purposely focused 
on specific sub-populations that are commonly associated 
with higher than average use of alcohol and traditional 
illegal drugs, such as cannabis, ecstasy, crack cocaine and 
heroin. The findings from this research revealed significant 
variations in both the prevalence of NPS use and the types 
of NPS used across these sub-populations. These variations 
in prevalence were often accompanied by distinct harms 
and support needs. In section 3, we provide the context and 
evidence for our recommendations for service development 
and future research agendas through an analysis of the 
quantitative and qualitative data.
Official sources of data (such as Public Health England’s 
JSNA support packs) highlight the relatively small number of 
substance misuse service clients who also report NPS use. For 
example, data from Public Health England (2015a) revealed 
that only four per cent (n=9) of young people accessing 
specialist substance misuse services in Manchester in 2014-
15 reported NPS use (compared to five per cent nationally). 
Furthermore, figures from Public Health England (2015b) 
show that only five new treatment entrants in Manchester 
in 2014-15 (compared to 1,154 nationally) reported NPS use 
as part of their club drug use. As we go on to highlight in 
sections 3.2 to 3.6, the reported use of NPS amongst the 
sub-populations focussed on in this research is much greater 
than that portrayed by these official estimates. 
3.2 Students  
In the UK, evidence from general population studies (such 
as, for example, the 2014/15 CSEW), suggests that the 
consumption of any type of NPS in England and Wales is 
more prevalent among young people, particularly males 
(Lader, 2015). Yet, as we noted in section 1, university 
students living away from home are likely to be exempt 
from such surveys, despite having much higher rates of 
recreational drug use than the national average (TAB, 2015). 
The student population in Manchester is a particularly under-
researched sub-population of substance users in the city. 
Manchester currently hosts over 105,000 students across 
four universities – Manchester University; Manchester 
Metropolitan University; the University of Salford; and 
the University of Bolton – resulting in one of the largest 
student populations in the UK and Europe (MIDAS, 2016). 
Many students are thought to be attracted to the city’s 
thriving dance music scene and renowned club nights at 
venues such as Sankey’s, The Warehouse Project and the 
Albert Hall. 
This sub-population was targeted via an online survey, with 
the primary aim of establishing existing NPS prevalence 
and drug trends amongst Manchester’s student population. 
The survey achieved a response rate of 134. Just over a 
fifth of respondents were male (n=31, 23 per cent), the 
remainder were female (n=103, 77 per cent). The mean age of 
respondents was 22. In stark contrast to national estimates 
(see section 1.5), 40 per cent (n=53) of respondents had tried 
NPS in the last 12 months. As can be seen in Figure 1 below, 
the most common NPS was by far nitrous oxide, with over 
two thirds (n=36, 68 per cent) of respondents claiming to 
have used nitrous oxide in the last 12 months. Again, this 
contrasts sharply with the 2014/15 CSEW (CSEW 2015) that 
found that past year use of nitrous oxide was reported by 
only 7.6 per cent of 16 to 24 year olds. 
In line with the poly-drug use exhibited by clubbers 
(see section 3.3), the survey found that, of the 36 
respondents who had taken nitrous oxide in the last 
12 months: 75 per cent had taken it with alcohol; 50 per cent 
with MDMA; 36 per cent with cocaine; and 31 per cent with 
cannabis. However, rather than taking NPS while clubbing, 
the vast majority (86 per cent) had taken nitrous oxide at a 
house party, with over two thirds (69 per cent) taking it in 
student halls. Only 44 per cent had taken nitrous oxide in 
a nightclub.
what they’ll do to you’ (83 per cent). In summary then, it 
can be seen that the NPS use amongst the students that we 
surveyed was primarily recreational use of nitrous oxide at 
house parties or in student halls of residence. It would appear 
that the main drivers for use were curiosity and peer pressure. 
When it comes to poly-drug use, the most common substance 
taken with nitrous oxide was alcohol, and to a lesser extent 
MDMA. The theme of poly-drug use is explored in more depth 
in the section on clubbers, and it is to this section that this 
report now turns.
Stimulants
Liquids
Nitrous Oxide
Hallucinogens
Figure 1: In the last 12 months, have you ever taken any of the following NPS? (n=53)
Synthetic Cannabinoids
100%80%60%40%20%0% 20% 30% 50% 70% 90%
Figure 2: “I’ve taken legal highs in the past because …” (n=48)
…I was curious
…taking NPS is normal among my friends
…friends have taken them
…they are better than other drugs
…they are safer than illegal drugs
…I was able to buy them online
…I knew I wasn’t breaking the law
…other drugs were unavailable
100%80%60%40%20%0%
Disagree Neither Agree
As shown in Figure 2 above, when it came to the reasons 
for taking NPS, over four fifths of the respondents had taken 
NPS in the past simply because they were curious, with 69 
per cent having taken them because their friends had. In 
contrast, three quarters disagreed with the statement that 
NPS are better than other drugs, and 63 per cent disagreed 
that they are safer than illegal drugs. Interestingly, of the 81 
respondents who had never taken any NPS, the most common 
reasons for not taking them were: ‘too risky, you never know 
what’s in them’ (81 per cent), and ‘too risky, you never know 
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3.3 Clubbers, NPS and poly-drug use
In their comprehensive review of UK and international 
evidence, Abdulrahim et al. (2016) highlight how the 
prevalence of drug use, relative to that in the general 
population, is high among young adults, ‘clubbers’ (those 
who frequently use the night-time economy and dance 
venues/nightclubs), and lesbian, gay, bisexual and trans 
(LGBT) populations (and MSM in particular). We focus in 
more detail on MSM in section 3.4. Here we outline the 
findings from our survey of clubbers. 
The research into NPS use amongst clubbers focused on 
six different music nights (drum & bass, hip-hop, deep 
house, commercial house, techno and trance) at a club in 
Manchester. As outlined in section 2.3, we analysed existing 
survey data collected from 2,139 clubbers; the largest in-situ 
study of clubbers conducted in the UK. The gender split was 
fairly equal with 47 per cent (n=1,005) of those surveyed 
being male, and the remainder female. The ethnicity of the 
clubbers was predominantly ‘White’ (88 per cent), with the 
next highest categories consisting of ‘Black British’ (three 
per cent) and Asian (two per cent). Although the mean age 
of clubbers was 23, ages ranged from 15 through to 52 years 
of age. 
Almost four-fifths (79 per cent, n=1,681) of those surveyed 
were current drug users, and of these, 85 per cent of males 
and 73 per cent of females reported having ‘ever tried NPS’. 
A tenth of male drug users and eight per cent of female drug 
users reported having ‘used NPS on the night’. The most 
popular NPS were from the stimulant category, ketamine 
and mephedrone. When compared to other drugs (i.e. non-
NPS) taken on the night, ketamine was the third most 
popular substance, after MDMA/ecstasy and cocaine, and 
mephedrone was the fifth most popular drug. Just over a 
quarter (27 per cent) of drug users reported having used 
ketamine in the previous month, compared to 15 per cent of 
those having used mephedrone. 
In relation to other NPS discussed in this report, nitrous 
oxide only made the top 10 substances used on the night 
on one of the survey nights: a techno night. In contrast, 
GHB was the seventh most popular substance used on the 
night for ‘techno’ and ‘deep house’ nights, with levels of 
consumption similar to ‘poppers’/amyl nitrate. Of the 1,681 
clubbers that reported using drugs, five per cent claimed to 
have used GBL in the past month. There is a well-trodden 
path of substance use trends first emerging in the LGBT 
community, before crossing over to clubbers and more 
general recreational drug use (see, for example, poppers, 
ecstasy and ketamine). As we discuss in section 4.3.5, this 
suggests the need to monitor the use of GBL in the wider 
population, in particular, specific night time economies 
including LGBT bars and clubs, and the electronic dance 
music scene. 
Of the 788 NPS users, just over a quarter (27 per cent) 
reported having had a negative experience after taking NPS. 
In comparison to traditional club drugs (such as MDMA and 
cocaine), NPS users typically discussed more intense and 
prolonged effects that could result in users being unable 
cocaine and ecstasy in recent years – there is no indication 
at present that another drug (as we have previously seen 
with mephedrone) is about to appear onto the clubbing 
scene. Nonetheless, one emerging finding from the research 
was a number of clubbers reporting snorting two or more 
drugs together. For example, respondents reported snorting 
a line of cocaine and ketamine – referred to as ‘CK’ – or a 
line of cocaine and MDMA, or what is referred to as ‘party 
lines’ consisting of a mixed line of stimulant type drugs, for 
example, cocaine, ketamine and MDMA. There was some 
evidence of the use of hallucinogens such as 2CB, Brome, 
Nexus, with past month use reported by 3.5 per cent of the 
sample and a small number of clubbers also talked of using 
DMT and ‘Changa’, a smoking mixture containing DMT and 
a monoamine oxidase inhibitor (MAOI) that both potentiates 
and elongates the DMT experience. As with the emergence 
of GBL onto the recreational clubbing scene, these are 
emerging trends that require monitoring. It was interesting 
to note that several users of ‘Changa’ and DMT had reported 
first using it at festivals in Croatia, and ‘party lines’ were 
reportedly first introduced to users whilst clubbing in Berlin. 
The potential for drug using trends to be introduced from 
other countries is a reminder of the effects of globalisation 
and how quickly new drug trends can develop.
In summary, the research found much higher levels of 
NPS use amongst this group than that found in national 
prevalence data, with much of the NPS use accounted for 
by ketamine and mephedrone, demonstrating the appeal of 
stimulant type drugs within this subpopulation. However, 
given the popularity of these two drugs, and the fact that 
they were classified under the Misuse of Drugs Act in 2009 
and 2010 respectively, many commentators are questioning 
how long they can credibly remain under the ‘NPS’ umbrella. 
The implications of these findings for service development 
and future research agendas are discussed in sections 4.2 
and 4.3. We now turn attention to another targeted sub-
population of NPS users, MSM who engage in chemsex.
3.4 Chemsex
Chemsex is defined by the use of any combination of 
drugs that includes three specific drugs (“chems”) before or 
during sex by MSM (Men who have Sex with Men). These 
three drugs are methamphetamine (crystal/crystal meth/
Tina/meth), mephedrone (meph/drone) and GHB/GBL 
(G/Gina). (ReShape & 56 Dean Street)
There is increasing evidence that there are three distinct, 
but overlapping, areas in which MSM populations bear a 
disproportionate burden of ill health: sexual health (notably 
HIV infection), mental health, and the use of alcohol, drugs 
and tobacco (Public Health England, 2014a). In particular, 
there is growing concern over the involvement of a minority 
of MSM in chemsex, a term primarily used to describe sex 
between men that occurs under the influence of drugs 
immediately preceding and/or during sexual encounters but 
not exclusive to MSM (Bourne et al., 2014). 
Although many interviewees suggested that chemsex was 
not a recent phenomenon – with many noting it has existed 
in the UK for around a decade – the profile of chemsex 
to sleep for between two and seven days. Other symptoms 
and side effects included: high body temperature; heart 
palpitations; panic attacks; and hallucinations and ‘bad 
trips’ which often led to panic attacks, physical injuries and 
even hospitalisation. 
‘I thought I was going to kill myself. Benzo Fury is the 
worst drug’. (22-year old Male)
‘I had some of that Charlie Sheen. Next thing I know I 
was found half asleep seeing aliens! I got taken home by 
the police, thought I was superman and tried to snap their 
handcuffs’. (24-year old Male)
The NPS that was discussed most often in relation to 
negative experiences was mephedrone. These experiences 
often centred around feelings of disorientation and confusion, 
as well as depression and suicidal thoughts.
‘I was hospitalised. I just span out and couldn’t move my 
body’. (23-year old Male)
‘I got really confused and tried to jump off the balcony’. 
(25-year old Male)
‘I had too much and felt suicidal’. (26-year old Male)
‘My brother stabbed himself repeatedly, [I’m] very scared 
of it’. (20-year old Female)
‘I took some and ended up really disorientated and crying’. 
(22-year old Female)
With this group of users, it appeared that such negative 
experiences had put some of them off using NPS, such 
as, mephedrone again. Yet, despite 27 per cent of users 
revealing bad experiences with NPS, only 10 per cent said 
they would ever consider seeking any form of support or 
information from substance user services, with many stating 
that drug services were for problematic users, committing 
crime to fund habits, such as, heroin and  crack users. 
Those who use club drugs often use more than one 
substance during a drug taking episode (see CSEW, 
2015). Our survey found that almost half (47 per cent) of 
the 2,139 clubbers were polydrug users on the research 
nights, with 91 per cent of those using drugs on the night 
also consuming alcohol. Clubbers were asked to state their 
favourite drugs and alcohol combination. Interestingly, other 
than ketamine, no other NPS were included in the top 10 
substance use combinations. These primarily included a 
combination of MDMA/ecstasy, cocaine, ketamine, alcohol 
and cannabis. The reported past month use of these drugs 
was considerably higher than national estimates of past year 
use: MDMA (48 per cent); cannabis (47 per cent); ecstasy (45 
per cent); cocaine (44 per cent); and ketamine (27 per cent). 
The latest 2014/15 CSEW data (CSEW 2015) on past year use 
is: cannabis (16-24 year olds, 16.3 per cent, 16-59 year olds 
6.7 per cent); cocaine (16-24 year olds, 4.8 per cent, 16-59 
year olds 2.3 per cent); ecstasy (16-24 year olds, 5.4 per cent, 
16-59 year olds 1.7 per cent); and ketamine (16-24 year olds, 
1.6 per cent, 16-59 year olds 0.5 per cent). 
Due to a combination of factors – including negative 
experiences with NPS and an increase in the quality of 
has recently been raised through the Vice documentary 
Chemsex and the film G O’clock that both centre on London’s 
chemsex scene. There have subsequently been high levels 
of media exposure and heightened discourse that has raised 
awareness of what was previously an underground scene. 
The health risks associated with chemsex are more severe 
than those associated with other scenes commonly linked to 
recreational substance use. Overdoses and black-outs linked 
to the use of GBL/GHB are common. Methamphetamine 
and mephedrone are also often injected (‘slammed’), thus 
increasing the risks of injection-related infections and blood-
borne infections like HIV – Manchester has the highest rate 
of diagnosed HIV outside London and the South East and 
account for half of all residents living with HIV in Greater 
Manchester (Manchester City Council Health Scrutiny 
Committee Meeting, 2016) – and HCV. In addition, the after 
effects of extended periods of drug use and sex for many 
hours are extreme fatigue and lack of sleep, and there are 
concerns about non-consenting sex. There is also the risk 
of the transmission of STIs. In 2014, gay and bisexual men 
were over-represented in cases of infectious syphilis and 
gonorrhea (Health Scrutiny Committee Meeting, 2016). Many 
of these issues can lead to: chronic depression; anxiety; 
weight-loss; paranoia; drug-induced psychosis; depression; 
and suicidal thoughts. The health care costs associated with 
chemsex include increased use of sexual health and HIV 
services, drug services and counselling services, and the 
potential loss of lifestyle stability (in terms of employment, 
debt, housing, partnerships and friendships). 
Sexual health services, and HIV services in particular, are 
increasingly aware of the association between drug use and 
high-risk sexual behaviours (see Department of Health, 2013). 
This is now reflected in strategic developments at national 
policy level, for example, the current Public Health England 
action plan ‘Promoting the Health and Wellbeing of Gay, 
Bisexual and Other Men Who Have Sex With Men’ (Public 
Health England, 2015c). At a professional organisational 
level, there is an increasing amount of guidance aimed at 
clinicians. The standards of care for people living with HIV 
developed by the British HIV Association (BHIVA) recommend 
screening for drug and alcohol misuse within three months of 
diagnosis, and annually thereafter, and that services should 
have appropriate referral pathways in place. The British 
Association for Sexual Health and HIV (BASHH) provides 
recommendations on screening for alcohol and recreational 
drug use in several of its guidance documents, including 
in the 2012 UK national guidelines on safer sex advice 
(Clutterbuck et al., 2012) and the 2013 UK national guideline 
for consultations requiring sexual history-taking (Brook et al., 
2013). The BASHH position statement on ‘club’ (recreational) 
drug use, published in 2014, is intended to increase 
clinicians’ awareness of the problem and provide information 
on screening, harms, interventions and referral pathways. It 
identifies MSM, young people, students and ‘clubbers’ as 
possible target groups to screen for potentially problematic 
use, and provides some proposed screening questions. It 
recommends that clinicians give simple safety advice and 
information on possible harm, including other sources 
of information, and that services should have agreed 
referral  pathways into appropriate local services 
(Sullivan et al., 2014). 
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Having outlined how chemsex is currently defined and 
the level of knowledge and guidance on developing 
appropriate service provision at a national level, we now 
turn attention to the findings and discussion around how 
chemsex should be defined locally, and how existing services 
need to develop. 
3.4.1 Defining chemsex in a local 
context
The definition at the start of section 3.4 was produced by 
ReShape (an activist think-tank that supports the need for 
new community responses to chemsex) and 56 Dean Street 
(the first UK GUM/HIV clinic to provide chemsex support to 
MSM around drug use, sexual health, and sexual wellbeing), 
and derived from the London chemsex scene. The stated aim 
of the definition is to help health workers and researchers 
understand differences between chemsex and other forms of 
recreational substance use. The definition applies specifically 
to MSM who are:
… disproportionately affected by HIV/STIs, and can be more 
likely to have a higher number of sexual partners. Chemsex 
is associated with some cultural drivers unique to gay men 
and communities that include psychosocial idiosyncrasies 
and new technologies (geo-sexual networking Apps) that 
can facilitate faster introduction to new partners, and 
to “Chems”. Chemsex commonly refers to sex that can 
sometimes last several days. There is little need for sleep 
or food. The heightened sexual focus enables more extreme 
sex, for longer, often with more partners and with less 
fear of STIs including HIV and HCV. Sharing injections is 
common. (ReShape & 56 Dean Street) 
Chemsex can be defined as the use of one or more of 
methamphetamine, mephedrone and/or GHB/GBL in a sexual 
context. Other recreational drugs can also play a role in 
chemsex, although they are deemed to be less prevalent and 
secondary to the use of the three main substances. However, 
despite the existence of this definition, the term chemsex 
and what it involves (in terms of drugs used) led to much 
debate and confusion during the research with members of 
Manchester’s LGBT community and professionals working 
with those involved in chemsex. 
‘Oh no, I don’t do that [methamphetamine, mephedrone 
and GHB/GBL]. … I use Grindr, I have sex on chems 
… [but] I just sniff coke and ket[amine] sometimes’. 
(41-year old MSM)
‘When I think of chemsex I think of meth[amphetamine], 
cocaine, speed, and all other alternatives and variations all 
working under the sort of stimulant kind of theme’. (30-year 
old MSM)
They [those involved in chemsex] tend to just stick to 
… Mkat [Mephedrone], crystal meth[amphetamine] and 
coke. They might still do a bit of GHB but they’re not really 
interested in pills anymore or speed’. (Sexual Health Nurse) 
‘I’ve had a few people that weren’t taking drugs 
at all, but were drinking and going out and having 
that, when compared to Manchester, London has a larger 
cohort of MSM using the ‘traditional’ chemsex drugs, and a 
higher percentage of those ‘slamming’. We therefore suggest 
that, while there is clearly potential for knowledge exchange 
and sharing of good practice with services in London, there 
is a need to better establish the prevalence and nature of 
chemsex in Manchester. 
While the scale of chemsex in Manchester appears to be 
much lower than that in London, a recurring theme in the 
interviews was the sharp escalation of the chemsex scene 
in Manchester. For example, all those MSM we interviewed 
made similar observations about the noticeable rise in 
references to chemsex and chemsex parties. 
‘Over the last couple of years, the random sort of requests 
for chemsex and chemsex parties that I get [through Apps] 
have skyrocketed. I don’t know what can account for that 
spike in popularity, but it seems really, really huge now 
up North. Maybe that just has to do with more people 
accessing Apps, and Manchester becoming this sort of 
internationally recognized sort of queer Shangri-La that it 
is, more people sort of moving here and visiting here on 
weekends and stuff’. (34-year old MSM Sex Worker)
Interviews with professionals based in sexual health clinics 
also highlighted an increase in the number of MSM involved 
in chemsex accessing services. The wide spectrum of those 
involved in chemsex was also frequently observed. 
‘This clinic now has quite a high proportion of gay men 
coming to the clinic. … Guys who you wouldn’t even think 
are doing chemsex are doing chemsex. It’s become the 
norm’. (Sexual Health Nurse)
‘The people we see at the REACH clinic … [are] like 
complete opposite ends of the spectrum. So you’ll 
get  a youngish really vulnerable lad who’s maybe 
doing sex work and a number of drugs. And then 
you’d get a doctor. … There’s not a typical stereotype’. 
(Chemsex Substance Use Practitioner) 
‘I know nurses who go to [chem]sex parties [and] I 
know doctors who go to [chem]sex parties’. (Sexual 
Health Nurse)
The research, however, identified a need for a more robust 
measure of prevalence in a local context.3 While there are 
some encouraging developments – for example, the addition 
of questions regarding drug use and injecting behaviours in 
the LGBT Foundations wellbeing assessments – we discuss 
the need for improved data recording and data collection of 
substance use trends in sections 3.7 and 4.3. 
3.4.3 Existing service provision
In November 2015, Public Health England produced guidance 
for commissioners on the commissioning and delivery of 
substance misuse services for MSM involved in chemsex 
(see Public Health England, 2015d). This guidance includes a 
number of prompts for commissioners around understanding 
the needs of the local MSM population in order to commission 
appropriate local services. It was evident that many of these 
unprotected sex and using drink to facilitate sex’. 
(Chemsex Substance Use Practitioner)
One male sex worker that was interviewed even discussed 
how he offered ‘chemsex light’, with the refusal to ‘slam’, 
and an agreement to the use of cocaine and ketamine (rather 
than methamphetamine, mephedrone and GHB/GBL). The 
evident confusion over exactly what chemsex involves led to 
a number of discussions about the need to define chemsex 
at a local level. 
3.4.2 The prevalence of chemsex in 
Manchester
With the current [London orientated] definition of chemsex, 
… if people are only self-identifying [as involved in chemsex] 
if they’re only taking one of those three drugs, you could 
potentially be missing loads of people. (LGBT Health 
and Wellbeing)
The exclusion of those who do not use methamphetamine, 
mephedrone and GHB/GBL may go some way to explaining 
the disparity in numbers between those accessing services 
in Manchester and those in London. 
‘They [the REACH clinic in Manchester] have seen 30 gay 
men using these drugs in the last year. We see 3,000 a 
month’. (Chemsex Practitioner, 56 Dean St, London)
It should be acknowledged that the London clinic is well 
established and the REACH clinic has only recently been 
established and hence service uptake is expected to increase 
as awareness improves with increased REACH clinic 
marketing and the development of the chemsex awareness 
campaign, currently scheduled to be launched in February/
March 2017. The campaign will be particularly targeted at 
high risk MSM (e.g. people collecting needles from needle 
exchanges), however, information will be available to all 
via a new website. The new campaign focuses on raising 
awareness of the potential harms, providing harm reduction 
advice and signposting people to appropriate services. This 
campaign will also help to educate and inform residents of 
how chemsex is defined and its parameters. 
Considering the position that Manchester holds as one 
of the largest LGBT communities in the UK, the numbers 
coming through services appears low. Particularly, as 
recent research has suggested that Manchester (along 
with Brighton) has the fastest growing chemsex scene in 
the UK (SIGMA, 2016). One of the reasons for this disparity 
may be the atypical nature of the London chemsex scene. 
Recently published findings from a national survey of 15,000 
MSM revealed a number of interesting differences (SIGMA, 
2016). For example, seven per cent of survey respondents 
in England claimed to have used at least one of the three 
chemsex drugs (methamphetamine, mephedrone and GHB/
GBL) in the last month. For those living in London, this 
figure rises to 14 per cent. In addition, those living in London 
were almost twice as likely (3.3 per cent) to have reported 
injecting drugs in the past year, compared to men living 
outside London (1.8 per cent). This evidence would suggest 
suggestions were already in place in Manchester, and well 
established ahead of this guidance. The research team 
attended steering group meetings at the REACH clinic, 
and conducted several interviews with sexual health and 
substance use professionals who were working with this 
user group, and it was clear that strategic commissioning 
and the integration of sexual health and substance use 
teams already exists. The REACH clinic is a partnership 
between the Hathersage Sexual and Reproductive Health 
Service (Central Manchester NHS Foundation Trust), where 
the service is currently located and the integrated drug and 
alcohol service, currently provided by CGL. In addition, there 
are clear indications of strong partnership working with 
the LGBT Foundation, George House Trust and other 
LGBT organisations. 
‘I think what they [the REACH clinic] have got now is a 
really good basis to build on. I think it’s in a good setting 
[and] the staff on the ground have got understanding of it 
[chemsex]. … It’s a very quick provision, so you can come 
in to see the drug worker, and if you need an STI screen, 
they’ll do that there. They’re very geared up to getting 
these people engaged, and that’s a massive part of the 
treatment’. (Senior Substance Use Practitioner) 
‘It’s an ideal partnership because to address chemsex you 
need to go to sexual health clinics for the risk assessments 
and care, you need the expertise of behavioural interventions 
that drugs services can provide, and you need an LGBT 
charity for the cultural competency that goes with LGBT 
experiences’. (Chemsex Practitioner, 56 Dean Street) 
As highlighted in the above quote, the inclusion of the LGBT 
Foundation on the steering group of the REACH clinic is a 
positive step that has helped ensure the cultural competency 
of the clinic. Cultural competency appears to be key when it 
comes to engaging those involved in chemsex into services. 
Indeed, one of the leading figures in the development of 
chemsex support suggested that, when it comes to staffing 
services, gay men should be employed where possible. 
‘I would populate it with gay men in the beginning, just 
because of their [those involved in chemsex] fear of 
approaching services. … Show us, you know, what you’re 
talking about. Give us a gay man who can talk about 
chemsex’. (Chemsex Practitioner, 56 Dean Street)
Most locally based professionals with experience of working 
with this user group suggested, however, that while 
representation of gay men within chemsex services is useful, 
other skills and expertise are equally, if not more, desirable.
‘It’s about the skill of the worker being able to engage 
that person. … It should be representative [but] I certainly 
don’t think it needs to be staffed by just gay men’. 
(Chemsex Substance Use Practitioner)
‘I think it’s more about the person being open and non-
judgmental and knowledgeable’. (LGBT Health and 
Wellbeing Service Manager) 
‘It’s about your willingness to learn. I think [even] if you 
identify as being in the same group as the people you’re 
targeting, it doesn’t necessarily mean you understand 
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their experience. You maybe have more insight into their 
experience, but you won’t know exactly what it’s like to 
be them. You still need to respect the person’s individual 
experience’. (LGBT Health and Wellbeing Service Manager)
So far, we have highlighted the importance of defining 
and establishing the prevalence of chemsex in a local 
context. We have also illustrated the need to ensure 
that the LGBT community are properly represented at all 
stages of provision, from strategic planning through to 
representation in services. We now turn our attention to 
some of the requests and suggestions that emerged through 
the course of the research in relation to developing existing 
service provision. 
3.4.4 Service development 
Despite considerable positivity regarding the establishment 
of the REACH clinic by members of the LGBT community 
and professionals who took part in the research, there was 
much discussion about the need to engage more with those 
involved in chemsex. For some, the discussion focused on 
improving the promotion of existing services. For others, 
the focus was on developing and expanding the services 
currently on offer. The following sections highlight the most 
frequently cited areas for development: opening times; 
service location; service promotion; targeted outreach; 
tailored service response; mental  health and counselling 
provision; and staff development.
3.4.4.1 Extended opening hours 
It was often noted that many MSM involved in chemsex 
are in full time employment. The REACH clinic operates 
on a Wednesday afternoon at the Hathersage Sexual and 
Reproductive Health clinic though follow-up support can also 
be obtained during other times in the week. 
‘The main thing is to make appointments available … 
outside of traditional nine to five working hours. … I can’t 
fucking get out of work on a Wednesday at four, and a lot 
of other people can’t’. (40-year old MSM) 
‘Night time would be really cool, if only because sometimes 
people do need a little bit of Dutch courage in order to 
actually access services. So you might get a lot more 
people who are just sort of like “Fuck, I’ve had a drink, 
I really should go to this place”. So, you know, ideally 24 
hours a day’. (24-year old MSM)
Whilst a 24/7 clinic is unrealistic, the REACH clinic have 
been responsive to feedback around opening times. It is 
encouraging to see that the appointment times have been 
moved to later in the day with the clinic now operating 
on Wednesday afternoons from 3pm-7pm. This enables 
appointments to be made outside the typical 9 to 5 working 
day. Furthermore, following the initial assessment at the 
REACH clinic, follow-up appointments can be delivered 
at other times during the week, either at the Hathersage 
Centre, CGL premises located across the city or at the 
LGBT-Foundation.
when it comes to working in these spaces, the need for 
cultural competence and sensitivity was emphasised.
‘I worked with [LGBT Charity in another UK city] for a 
while and as part of my training they had me go to some of 
their pop-up clinics, and like different bars. And I thought 
“Wow, that’s really, really effective”. … [We] had to make 
ourselves as small, but as visible as possible, so as not to 
put people off, because I think people tend to get really 
annoyed by over-zealous sexual health practitioners, 
especially in social spaces’. [36-year old MSM)
‘We’ve been doing late night outreach, … trying to reach 
groups of MSM who we don’t believe access our services 
at the moment. … An example is we go to [a local fetish 
night] every four weeks. It’s taken us quite a while for them 
to let us attend, because obviously what they don’t want is 
a service going round shaking condoms in people’s faces. 
… It’s quite difficult because they were saying “If you want 
to come in, you have to come in fetish gear”, and it’s not 
appropriate. … We’ve found ways round it. We wear black 
t-shirts with something over the top [of them] like a body 
brace or something like that. … So we’re not wearing bright 
yellow LGBT foundation t-shirts, we blend in, but we’re still 
visible’. (LGBT Health and Wellbeing Service Lead)
As outlined below, while discussions often focused on 
targeting the physical locations frequented by those involved 
in chemsex, they also covered the need for outreach work in 
virtual spaces. As highlighted at the start of this section, the 
use of Apps such as Scruff, Growlr and Grindr are central to 
defining what chemsex encompasses. In support of this, all 
MSM that we spoke to referred to the use of various Apps 
when discussing the chemsex scene. The centrality of Apps 
to the chemsex scene led many interviewees to discuss the 
need for a web-based presence, where services can interact 
and promote what they do via Apps. 
‘It’s really important I think to have that sort of mobile 
accessibility. That would probably get people a lot more 
engaged, and at least get people more confident about their 
ability to get information’. (24-year old MSM Sex Worker)
‘I’m not sure if the NHS operates any sexual health Apps or 
anything, [but] that would be really, really useful. … A way 
that people could find out where their nearest clinics and 
testing times [are], and all that kind of stuff for different 
things. Just really discretely and really simply’. (34-year old 
Male Sex Work) 
‘I’m assuming that most App users are between, what, like 
18 and 30. … Addressing those people through the Apps is 
a good idea’. (34-year old MSM)
Once again, it was very positive to discover that some of 
this ‘virtual’ outreach and support is already happening 
in Manchester. Greater Manchester local authorities have 
commissioned and funded the LGBT Foundation to develop 
some innovative methods of engagement with App users. 
‘We’ve done [virtual] outreach for the past couple of years, 
going on Grindr and Gaydar and stuff, offering information, 
support and advice. In the last 12 months we’ve started 
doing late night sessions, so on a Friday night we’re online 
3.4.4.2 Service location
The need for service provision in the city centre, and 
specifically in the village, was consistently raised by MSM, 
sexual health and substance use practitioners. Pop-up clinics 
were also widely suggested. 
‘I mean the city centre is an obvious choice. In and 
around Canal Street, again really obvious choice’. (34-year 
old MSM)
‘A city like Manchester should have fucking pop-up HIV 
testing and just general sexual health places on every 
fucking corner you know. Sorry, it just really annoys me’. 
(34-year old MSM Sex Worker)
However, despite taking on board these suggestions, the 
feasibility of developing these services was often questioned 
by service providers and ultimately, the suggested changes 
for service provision provided here appear to fall outside 
what is practical within current resources. 
3.4.4.3 Service promotion
In addition to the physical location of services, the issue 
of how existing services, such as the REACH clinic, could 
better promote the services they offer was often talked about 
during interviews. Discussions commonly centred  on what 
the services’ promotional material should look like, and 
where it should be made available.
‘I don’t know if the LGBT foundation, or any other sort of 
sexual health clinics here do sort of like business card sized 
things that say “These are the services we provide, this is 
the counselling we do, these are the hours”. That would be 
really cool. … People can just pop in, pick it up and leave’. 
(34-year old MSM)
It was also noted that many MSM do not frequent the village, 
and as such, other popular night time economy areas should 
be targeted. Some of the most popular suggestions included 
the Northern Quarter and non-city centre areas, such as 
Chorlton and Didsbury. 
‘I just feel like that sort of [promotional] material should be 
everywhere’. (34-year old MSM Sex Worker)
3.4.5 Targeted outreach
In addition to suggestions of where services should be 
located and how they should be promoted, the need for 
more targeted outreach was frequently discussed. Bourne 
et al. (2014) have shown that the use of methamphetamine, 
mephedrone, GHB/GBL and ketamine was associated with 
attendance of gay cafes, bars, pubs and clubs. They also 
found that gay and bisexual men who used any or all of 
these substances were more frequent attenders of these 
venues than gay and bisexual men who used none of them. 
Furthermore, they suggest that sauna use and the use 
of backrooms or sex clubs were also associated with the 
consumption of these drugs. Bars that hold fetish nights and 
city centre saunas frequented by MSM were identified as 
two key locations for outreach work. As touched on earlier, 
between 8 and midnight. And we are going [online] on 
Saturdays to try and reach a slightly different cohort of guys 
than we would during the earlier evening outreach. … We’ve 
talked to a lot of guys about chemsex on those forums. I 
think because there’s a level of anonymity, it means that 
people are being a lot more upfront with us, and people are 
being a bit braver when it comes to asking for advice as 
well. Because sometimes we might see people that come to 
clinics or face-to-face services, and only when we’ve seen 
them a few times do they tell us what they want from us. 
… We’ve got our own profile on Grindr as well so we can 
send targeted messages, which is a great way of promoting 
services like the REACH clinic’. (LGBT Foundation Service 
Engagement Lead)
3.4.6 Tailored service response
It was often noted by interviewees that those involved in 
chemsex need a bespoke service response. Many felt that 
services needed to better understand the needs of those 
involved in chemsex, and develop their services accordingly. 
Not only in relation to what/how information, support and 
advice is provided, but also – and importantly for this group 
– in relation to the provision of needle exchanges. 
‘When you start thinking ahead to how you could actually 
provide a service, or set up a service, you’re looking at who 
is your target group. What are you going to offer them? 
… Safer injecting techniques, clean needles. … You’d have 
counsellors there who could help support with the drug 
use. … What is out there right now for some of the drugs 
that they’re using? Nothing. Do we give anything? … What 
do we give for cocaine? What do we give for crystal meth?’ 
(Sexual Health Nurse)
‘I remember seeing a few guys that just wanted some 
more information about injecting and the dangers, and a 
bit of advice. That’s all they wanted, … they just wanted 
a conversation with someone’. (Chemsex Substance 
Use Practitioner)
‘We need to work differently. […] because a lot of people 
probably wouldn’t access a needle exchange, because they 
associate it with opiate drug users. There’s so much stigma 
I think attached to using a needle exchange’. (Senior 
Substance Practitioner) 
‘I think the village needs a needle exchange, … at the 
weekends in particular. Because that’s the other thing isn’t 
it. … Needle exchange provision at the weekend is limited’. 
(Senior Substance Use Practitioner)
When it comes to developing services for those involved 
in chemsex, there are examples of good practice 
elsewhere in the country. For instance, 56 Dean Street in 
London  have developed workshops and support for MSM 
that include: groups that explore issues such as safely using 
online sex Apps and sites; a group that examines 
‘sober-sex’; a needle exchange facility; safer injecting 
support; and information that specifically addresses 
methamphetamine and mephedrone injecting (see Public 
Health England, 2015d).
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Before moving on to look at mental health provision, it is 
worth heeding a warning from a practitioner at 56 Dean 
Street who felt that developing services that focus too 
heavily on developing needle exchange provision, would 
be to the detriment of those involved in chemsex who do 
not inject.
‘About 29% of our [chemsex] population are injecting, … 
[yet] the ones who are not injecting are exposed to just as 
much risks in regard to chemsex. It’s the HIV negative guy 
who’s doing G and sniffing mephedrone, who’s having sex 
with 15 partners who’s going to catch HIV and transmit it to 
30 more in the next month. That’s the highest risk. … A HIV 
positive man who’s injecting crystal meth, who takes his 
medicines regularly is very low-risk for a lot of things. … As 
a public health concern, [with] the transmission of disease 
and epidemics, that HIV positive man who’s injecting is 
lower risk than the other’. (Chemsex Practitioner, 56 Dean 
Street, London) 
This combination of factors associated with chemsex has 
been described as ‘a perfect storm for transmission of both 
HIV and HCV, as well as a catalogue of ensuing mental 
health problems’ (Kirby & Thornber-Dunwell, 2013). 
3.4.7 Mental health and counselling 
‘Mental health services would be a really, really good thing 
to get on board’. (30-year old MSM)
Another area of service development that was frequently 
discussed was better integration of mental health provision 
into existing services. Reasons for engaging in chemsex 
that were highlighted by counsellors, sexual health 
practitioners and substance use practitioners included: 
to overcome intimacy issues; fear of rejection and sexual 
shame; to cope with stigma over HIV/HCV; to deal with 
problems/trauma in the past; and to overcome internalised 
homophobia. According to the UK Household Longitudinal 
Study, MSM are twice as likely to be depressed or anxious 
compared with other men (McFall, 2012). Similarly, other 
studies have shown that LGBT adolescents are at greater 
risk of depressive symptoms and suicidal ideation than are 
heterosexual adolescents (Almeida et al., 2009; King et al., 
2008). Recent Public Health England guidance suggests that 
a better understanding of these factors is a prerequisite for 
improved treatment responses, including for problems related 
to substance misuse (Abdulrahim et al., 2016). Therefore, we 
suggest that the next stage in the development of integrated 
service provision for LGBT and particularly MSM, should 
incorporate counselling, including relationship counselling, 
and mental health support. The integration of mental health 
provision was often called for during interviews with a range 
of professionals working with this population. 
‘Drug use in general can be a way to self-medicate. … 
There might be some significant overlap with people who 
access mental health services and people who have regular 
chemsex’. (34-year old MSM Sex Worker)
‘For many, I think there is a deep rooted reason around 
stigma, shame, identity, even internalised homophobia, 
In addition, the need for both users and frontline practitioners 
to be aware of how particular drugs interact with specific 
medications was highlighted repeatedly in the interviews. 
In particular, the risk of overdose and death may depend on 
the type of HIV medication prescribed.
‘GHB/GBL can also cause severe nausea, vomiting 
and gastro-intestinal irritation, which will all adversely 
affect absorption of the antiretroviral agent’. (Chemsex 
Clinic Practitioner)
‘I think people forget that some of the other drugs, the 
recreational drugs, have an effect and can compromise the 
antiretroviral treatments. But also, they can enhance them 
and exacerbate them, turn them into more of a poison, 
either the antiretrovirals or the drug itself, the recreational 
drug. … So it can weaken the HIV drugs, which is not good, 
or it can double or treble the strength of it, which is not 
good either’. (Sexual Health Nurse) 
A consideration of other prescribed medications, such as 
anti-depressants, is also essential due to the potential to 
cause ‘serotonin syndrome’ when mixed with illegal drugs 
such as MDMA. There is a need to ensure that frontline 
staff – GPs, emergency medical staff, and sexual health 
and substance use practitioners – are all aware of the 
chemsex scene, drug interactions and contraindications, 
and the potential for increased toxicity. Drug use and poly-
drug use may interfere with adherence to, as well as the 
effective¬ness of antiretroviral therapy (ART) (Antoniou & 
Tseng, 2002). Recreational drug use has consistently been 
linked to lower rates of HIV medication adherence (Halkitis 
et al., 2005; Haubrich et al., 1999; Romanelli et al., 2003), 
with even lower levels among poly-drug users. There is also 
some evidence of a dose-response relationship between 
the use of certain drugs and medication adherence, which 
suggests that bingeing or heavy use may have a particularly 
detrimental effect on medication adherence (Braithwaite et 
al., 2005), although this needs to be investigated further. 
Issues of adherence to HIV medications in the context of club 
drug use by MSM are likely to become more significant if 
PrEP (pre-exposure prophylaxis) becomes a more prominent 
element of HIV prevention. The use of drugs by HIV-
positive individuals who have been prescribed antiretroviral 
medications is therefore a source of concern in terms of 
both compliance (Antoniou & Tseng, 2002) and serious 
drug interactions (Antoniou & Tseng, 2002; Romanelli et 
al., 2003). Adverse interactions between agents commonly 
prescribed for HIV infection and recreational drugs may 
also have serious clinical consequences (Connor, 2004; 
Pacifici et al. 2001a, 2001b; Harrington et al. 1999; Henry 
and Hill, 1998). For example, GHB/GBL is known to interact 
with ART by lowering the seizure threshold and should 
be used with caution in HIV-positive patients predisposed 
to seizure disorder (e.g. those with toxoplasmosis, 
cryptococcal meningitis) (Romanelli et al., 2003). It has been 
recommended that HIV-positive patients who use GHB/GBL 
be warned about the potential dangers of drug interaction 
with protease inhibitors (especially ritonavir). Other drugs, 
such as MDMA and ketamine, are also known to interact 
with ART (Romanelli et al., 2003). 
that their use of drugs and involvement in chemsex is 
masking’. (LGBT Counsellor)
‘The most extreme client that I had was a client that 
presented at generic drugs services. … He was just chemsex 
all week, day and night. … [And] his mental health, … [he 
was] suicidal every week. … Then he got sectioned a 
few times. … He had HIV, and now he’s in Strangeways’. 
(Chemsex Substance Use Practitioner)
Central and North West London NHS Foundation Trust have 
established a ‘Club Drug Clinic’ that provides a service 
tailored to the needs of club drug users. The clinic is a 
prime example of how a number of key services have been 
integrated together. For example, the clinic offers medically 
assisted withdrawal from substances including GHB/GBL. It 
also prescribes medication to help manage the side effects 
of coming off stimulants such as mephedrone and other 
substances. Specialist addiction doctors and psychologists, 
nurses and counsellors provide advice and support, as do 
peer mentors who have experienced and overcome similar 
problems. On-site sexual health screening and support is 
available, along with liaison and referral for mental and 
physical health problems (including bladder and kidney 
problems, and HIV and other blood-borne viruses). The 
clinic works in close partnership with ‘Antidote’, a LGBT 
drug and alcohol service (see Public Health England, 2015d). 
This provides a model for the development of services 
in Manchester. 
3.4.8 Staff development 
Interviewees identified a number of training issues for 
staff, including risk of overdose, cultural competency and 
contraindicated substances. Overdosing is a particular risk 
associated with the use of GHB/GBL. There is a fine line 
between the correct amount needed to get the desired 
effects and overdosing. Overdosing is common if doses are 
not carefully measured, or if they are taken consecutively 
two quickly (usually within two hours). 
‘We are seeing on average six people each weekend with 
suspected overdose on G [GHB/GBL] at one hospital,  
St Thomas’s, alone in London’. (Chemsex Practitioner,  
56 Dean Street)
Added to this, taking GHB/GBL with other depressant drugs 
(such as alcohol, tranquilisers or ketamine) can lead to 
unconsciousness and comas. There is a clear need to ensure 
that frontline staff are educated about chemsex and properly 
trained in how to deal with overdoses related to chemsex 
drugs, such as, GBL/GHB and crystal methamphetamine. 
More generally, though, there is a need to ensure substance 
use practitioners are culturally competent and knowledgeable 
in relation to this user group. 
‘Everyone’s aware of chemsex now a little bit, but you 
need someone that knows what they’re talking about in 
the services for those people that do present, … otherwise 
you’ll just lose them very quickly. The same way you’d lose 
anyone that presented to any service that didn’t know what 
they’re talking about’. (Senior Substance Use Practitioner)
In summary, the research identified a number of specific 
user needs, areas for potential service development and 
staff training needs that are specific to the chemsex scene. 
We now turn our attention to another group of NPS, 
synthetic cannabinoids.
3.5 Synthetic cannabinoid use 
amongst vulnerable groups 
‘I want people to realize what it’s doing, know what I 
mean? Like, what it’s like. It’s killing us all, we’re slowly 
getting killed’. (18-year old Homeless Female)
Synthetic cannabinoids were first detected in the UK and 
other European countries towards the end of 2008. They are 
produced with manufactured chemicals that create similar 
effects to delta-9 tetrahydrocannabinol (THC), the active 
ingredient in cannabis. These powdered chemicals are mixed 
with solvents and added to dried herbs or plant matter, or 
increasingly sold in powder form. In 2014, 30 new synthetic 
cannabinoids were identified, bringing the total number 
reported to the EU Early Warning System to 134 (EMCDDA, 
2015). Synthetic cannabinoids are the largest group of 
substances monitored by the EMCDDA, reflecting the rapid 
pace in which manufacturers can produce and supply new 
cannabinoids in order to circumvent drug laws. In 2013, over 
21,000 seizures  were reported, comprising more than 40% 
of the total number of seizures for NPS (EMCDDA, 2015). 
We begin this section with an overview of the findings 
from a survey coordinated by Homeless Link in partnership 
with: MASH (Manchester Action on Street Health); the 
Booth Centre; Lifeshare; Justlife; Barnabus; and Salford 
Loaves and Fishes. The survey involved 53 respondents 
who were engaged with various homeless services in 
Manchester. Of those that were surveyed, just over two 
thirds were male (68 per cent, n=36) and 32 per cent were 
female (n=17). The ages of those surveyed ranged from 
17 to 49, with an average age of 30. Just over half 
(53 per cent, n=28) were classed as sleeping rough on the 
streets; 13 per cent (n=7) were housed in their own tenancy; 
11 per cent (n=6) were housed in a hostel/supported 
accommodation; nine per cent were housed in temporary 
accommodation (e.g. a Bed and Breakfast); six per cent (n=3) 
were housed in emergency accommodation; and four per 
cent (n=2) were sofa surfing.
The vast majority of rough sleepers (93 per cent, n=26) had 
taken NPS in the 12 months prior to the survey, compared to 
less than two thirds (64%, n=16) of non-rough sleepers (see 
Figure 3 p26). In addition, of the 42 respondents who had 
taken NPS in the 12 months prior to the survey, only a tenth 
(n=4) had taken just NPS. The majority (81 per cent, n=34) 
had taken between one and three other drugs in addition to 
NPS (see Figure 4 p26). These drugs were primarily Cocaine, 
Cannabis and Crack (see Figure 5 p26).
Of those who had taken NPS in the past 12 months (n=42), 
64 per cent (n=27) had taken them every day, and 14% (n=6) 
had taken them five or six days a week. Interestingly, a 
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higher proportion of rough sleepers had taken NPS at least 
five days a week than non-rough sleepers (85 per cent 
compared to 69 per cent).
The high levels of synthetic cannabinoid use reported in 
the homeless survey were confirmed by the qualitative 
interviews conducted with practitioners working with this 
user group and members of the homeless  community who 
estimated this figure to be even higher.
‘I’ve probably got about 40 clients on my caseload at the 
minute who are street homeless. Of them I’d say about  
95 per cent of them take Spice’. (Support Worker for Young 
Street Homeless) 
‘You’d be surprised how many people. … I’d say 99 per 
cent of them are Spice heads’. (Young Person’s Homeless 
Support Worker)
‘It’s everywhere, it’s absolutely everywhere. … It’s really rife 
[amongst Manchester’s homeless community]’. (23-year 
old Male, Street Homeless)
‘Every single person I know smokes it’. (Male, late 20s, 
Homeless GP Drop-in)
‘When I used to be homeless, everybody was smoking it’. 
(21-year old Female, Ex-Homeless)
3.5.1 Motivations and onset of 
synthetic cannabinoid use
Our current understanding of NPS consumption and the 
motivations for use is largely taken from: national and 
international studies of recreational drug using populations 
(see Winstock, 2011; Measham et al., 2011a; Measham & 
Moore, 2009; Wood et al., 2012a, 2012b); online surveys 
(see Carhart-Harris et al., 2011; Global Drug Survey, 2015); 
household surveys (see Home Office, 2012); or research with 
young people (see Castellanos et al., 2011; Champion et al. 
2016; European Commission 2011, 2014). In this section of 
the report, we turn our attention towards user groups – 
the homeless and offender populations – who are absent 
in conventional research and whose substance use ought 
not be defined as recreational. In doing so, we document 
how one particular group of NPS – synthetic cannabinoids 
– is widely used amongst this sub-population. We describe 
the primary motivations for the consumption of synthetic 
cannabinoids in this setting and the impact consumption 
has upon users’ health. 
For many of the survey respondents (see Figure 6 p27), the 
primary reason for using NPS in the preceding 12 months 
did not appear to be as a result of them being legal (3 per 
cent, n=1) or more effective than other drugs (7 per cent, 
n=2). Rather, it was simply because they were convenient 
and easily accessible (45 per cent, n=13). With this in mind, 
it is unsurprising that over ninety per cent of those who had 
used NPS in the preceding 12 months had bought them from 
a headshop (93 per cent, n=37) and/or newsagent (60 per 
cent, n=24). Only six (15 per cent) had bought them from a 
street dealer.
Recent annual Inspectorate of Prisons Reports have 
highlighted the Spice4 epidemic that has spread across 
the England and Wales prison estate. The prison system is 
churning out Spice users at an alarming rate. It is estimated 
that as many as 60 to 90 percent of the 90,000 prison 
population are regular users, equating to between 54,000 to 
81,000 prisoners using Spice at any one time (RAPt 2015). 
In our research amongst Manchester’s homeless community 
and buyers of synthetic cannabis in city centre headshops, 
many users who report daily use, dependency and a range 
of mental and physical health concerns (that we discuss later 
in sections 3.5.3 and 3.5.4) recounted first being introduced 
to Spice in custody.
Figure 5: Drugs taken in addition to NPS in last  
12 months (n=42) 
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Figure 4: Number of drugs taken in addition  
to NPS in last 12 months (n=42) 
‘The whole of the city centre, there’s a problem now in 
Manchester City centre. It’s the worst I’ve ever known it 
really’. (Homeless Outreach Worker) 
‘Huge problem. I think for a good six months, it’s 
been coming and getting worse and worse. People use 
it daily in this building, especially Spice’. (Supported 
Housing Manager) 
Figure 6: In the last 12 months, what is your main reason for using NPS? (n=42)
Convenient and easy to get
Cheaper than other substances
Substitute for other substances
More effective than other substances
They are legal
50%45%40%35%30%25%20%15%10%5%0%
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Figure 3: In the last 12 months, have you taken any of the following? (n=53)
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‘I first tried it in Forest Bank’. (23-year old Male, Homeless)
‘I tried it when I was in prison, and then I’ve smoked it 
since then’. (24-year old Male, Homeless)
‘I chose to use this [Spice] while I was in prison. If I 
didn’t go to prison I wouldn’t be on this legal high stuff’. 
(Male, mid-20’s, Synthetic Cannabinoid user, interviewed 
in City Centre Headshop) 
On release from custody many offenders will find themselves 
living in approved premises, supported housing or in 
emergency access accommodation. A zero tolerance policy 
to substance use is often employed that includes drug tests, 
breathalysers for alcohol use and room searches. The non-
detectability of Spice is a key motivation for use in these 
settings with users often reporting no distinct smell in 
comparison to the strong, pungent smell of ‘skunk’ which 
makes up over 80 per cent of the existing UK cannabis 
market (Home Office, 2015). Alcohol can also easily be 
detected on the breath of users.
Most other people we spoke to in the homeless community 
had first started using synthetic cannabinoids after becoming 
homeless, due to its high prevalence within the community.
‘I first started using when I started hanging around with 
homeless and that’. (18-year old Female, Homeless) 
In recent years we have seen the introduction of legislation 
prohibiting drinking in public places, especially the city 
centre where most homeless people cluster. Synthetic 
cannabinoids, unlike skunk cannabis, can be smoked quite 
openly and blatantly in the presence of Police and PCSOs 
because it does not have a detectable smell, making it a 
preferred choice for those spending time in public places, 
such as Piccadilly Gardens. 
City centre spaces also typically host the majority of 
local outlets that sell NPS. Until the recently introduced 
Psychoactive Substances Act 2016, many headshops and 
newsagents sold synthetic cannabinoids for £10 per 1 to 
1.5gram pack. Many also offered deals, such as, three packs 
(between 3 and 4.5 grams) for £20. In comparison, a typical 
£20 deal of skunk cannabis contains 1.2 to 1.5 grams. In 
addition, due to the potency of synthetic cannabinoids – 
often reported to be 50 to 100 times stronger than skunk 
cannabis – a much smaller amount is required per ‘joint’, 
making synthetic cannabinoids particularly appealing for 
economically disadvantaged groups including vulnerable 
young people, the homeless community and recently 
released offenders. 
When speaking to users in approved premises who were 
under license conditions and practitioners who worked with 
them, the same reasons synthetic cannabinoids are popular 
in custody – their non-detectability in Mandatory Drug Tests 
coupled with the addictive qualities we discuss in section 
3.5.3 (see Ralphs et al., 2016) – were discussed as key factors 
in the continued use of NPS beyond the prison environment. 
The following member of staff from an approved premises 
describes a typical drug testing scenario and how some NPS 
are not detectable.
Case Study 1: Jade5 
Jade is an 18-year old girl who describes herself as 
having had “a bad childhood”, running away from 
home on several occasions and spending periods 
of time in care. Since the age of 17, she has been 
surviving as a ‘rough sleeper’ on the periphery of 
Manchester’s homeless community and it is through 
her contact with the homeless that she was introduced 
to Spice. Initially she smoked it because it made her 
“feel warm”, helping her to sleep and temporarily 
forget her problems. However, she admits she quickly 
became addicted, getting into a pattern of “sleep, wake 
up, joint, sleep, wake up, joint – that was it”. At one 
point she was being hospitalised 3 or 4 times a week, 
sometimes even twice in the same night, having been 
found “passed out on the street”. Jade is aware of the 
dangers of Spice, both to herself and to the homeless 
community as a whole “It’s slowly killing us” she says, 
“It’s slowly killing me in my head”. She wants to stop 
using but finds withdrawal symptoms difficult to deal 
with – “you’re shaking, you got a headache, you got a 
bellyache, you can’t sleep, you’re proper wide-awake, 
it’s horrible, it’s really horrible”. During one withdrawal 
episode she got so ‘rattled’ she physically assaulted 
a 13-year old boy, something which she regrets and 
claims is totally out of character. To fund her addiction 
she admits to having stolen from her family and has 
resorted to prostitution to pay off ‘debts’. 
Unsure as to what services were available to her, Jade 
has sought help but this has so far proved unsuccessful. 
She originally approached ADS but was told she was 
too young. She now has an appointment with 42nd 
Street but this has been a long time coming; “I’ve been 
waiting since I was 16 for all this counselling stuff, now 
‘For instance, this morning [when I came on shift] it was 
handed over to me that somebody was under the influence 
of something last night. … So we got him down [from his 
room] and drug tested him. Our drug tests show cannabis, 
benzo’s, amphetamines, methamphetamines, opiates and 
cocaine. … While I was actually testing him this morning, 
he was clearly under the influence of something, he could 
hardly sit up in his chair, he was slurring his speech, he 
was sort of falling forward asleep and then falling sideways 
asleep. [But] he come back negative for everything, which 
would probably indicate that he’s been using legal highs’. 
(Approved Premises Staff)
As we highlight in sections 3.6, 3.7 and 3.9, our findings 
suggest that the consumption of synthetic cannabinoids 
presents particular problems for the offender population and 
the management of them, both within and beyond the prison 
environment. As we discuss in section 4.3, further research 
is required to understand the impact of NPS in local approved 
premises and custodial settings. We now turn our attention 
to the reported problematic use of synthetic cannabinoids 
amongst vulnerable users. 
that has traditionally exhibited higher than average levels 
of substance use dependency and mental health needs (see 
Homeless Link, 2014). 
The Homeless Link’s 2014 Health Audit revealed that 66 
per cent of the 2,500 homeless people surveyed reported 
they were recovering from a drug (39 per cent) or alcohol 
(27 percent) problem. The audit also found that poor mental 
health was a significant contributing factor to substance 
use with 80% of those surveyed reporting at least one 
mental health issue, and almost all of these reporting 
the use of drugs and/or alcohol as a coping strategy 
(Homeless Link, 2014). 
‘They’ll just have a really strong joint … to help them 
sleep and just block it out really, block out life’s traumas’. 
(Homeless Day Centre Manager) 
Although prevalence and dependence is very high amongst 
the homeless population in Manchester, the UK’s prison 
population has similarly high levels of drug dependency and 
poor mental health. The Prison Reform Trust (2016) estimate 
around three-quarters of UK prisoners have pre-existing 
mental health problems with many suffering from two or more 
mental health conditions, and around 20 per cent having four 
or five major mental health disorders. Indeed, past research 
has estimated that levels of psychiatric disorders among 
the male prison population are 14 times greater than in the 
general population (Singleton et al., 1998). The widespread 
use of synthetic cannabinoids in prisons has recently been 
connected to an increase in suicides and incidents of self-
harm (Prisons & Probations Ombudsman 2015; Ministry of 
Justice 2016a). 
By focusing on the homeless community, and those recently 
released from prison and living in supported housing 
or approved premises, this section aims to increase our 
knowledge and understanding of synthetic cannabinoids 
amongst a group that has traditionally exhibited higher than 
average levels of substance use dependency and mental 
health needs. We begin this section by exploring the links 
between NPS use and addiction. 
3.5.2 New psychoactive substances, 
same old problematic users 
‘It [Spice] has replaced a lot of other drugs. I’ve had three 
and a half, four years homeless on the street and a lot of 
my friends have given up heroin and crack addictions, 
and they now smoke the Spice. I’m the same. I’ve given 
up an alcohol, crack and heroin habit and I just smoke 
Spice. I give up cannabis as well’. (Male, mid 20’s, 
Supported Housing)
The research identified that the highest prevalence and 
problematic use of NPS – primarily synthetic cannabinoids, 
referred to generically as Spice – is amongst the same 
vulnerable groups that have traditionally been associated 
with problematic Class A substance use. Indeed, many 
dependent users of synthetic cannabinoids referred to past 
problematic use of other substances, typically heroin and 
crack cocaine. The highest levels of reported problematic NPS 
use in Manchester centered on the homeless community, and 
those recently released from prison and living in supported 
housing or approved premises. 
Evidence of the health harms associated with synthetic 
cannabinoid use within general population samples has 
recently emerged from several countries. Their consumption 
has been linked to a wide range of negative physical and 
mental health effects, including: addiction; aggression; 
agitation; muscle spasms; ‘fitting’; seizures; depression; 
hallucinations; paranoia; psychosis; self-harm; and 
suicidal thoughts (Barratt et al., 2013; Bebarta et al., 2012; 
Castellanos et al., 2011; Every-Palmer 2011; Harris & Brown, 
2013; Hurst et al., 2011; Thomas et al., 2012; Van der Veer 
2011; Zimmerman et al., 2009). A further compounding 
issue is that many users report that the effects are variable 
and unpredictable, even when using the same brand of 
synthetic cannabinoid (see Castellanos et al. 2011). While 
this body of research has usefully highlighted the harmful 
physical and mental health effects of synthetic cannabinoid 
use, they were undertaken with general population users. 
To date, there is a dearth of in-depth research exploring 
how synthetic cannabinoids affect more vulnerable groups in 
society, such as those in the homeless community; a group 
I’m nearly 19 and it’s only just coming through”. The 
supported housing scheme in which she currently has 
a place is actually increasing her likelihood of using 
because “everyone there smokes Spice – literally I 
cannot get away from Spice there”. Jade relates how 
those in the homeless community, who used to “stick 
by each other”, are now attacking and stealing from 
one another – “like battering someone to get spice, 
they’ll just batter him because he’s got spice, and rob 
it off him”. Having seen numerous assaults and even 
witnessed someone die on the street, Jade has to live 
with the fear of being attacked and of dying. As she 
says – “I’ve had a lot of bad experiences. It’s horrible. 
Spice has made my life hell really”.
Case Study 2: John
John is a 39-year old male. He is an intelligent, 
articulate and well-educated individual, self-employed 
and running his own small company. He has a wide 
experience and knowledge of drug use having started 
experimenting when he was 14 years old. For over 10 
years, he says he was addicted to heroin and crack but 
has been free of these for two years, although recently 
he has been a sporadic user of NPS, particularly 
synthetic cathinones. Despite describing himself as an 
ex-heroin and crack addict, he is of the opinion that 
‘traditional’ drugs are ‘safer’ because their effects are 
better understood and there are treatments available 
that help alleviate the symptoms of withdrawal. 
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3.5.3 The new heroin? Addiction, 
tolerance and dependence
‘People need to understand the stuff. Understand what it 
is, and how readily available it is. How easy it is to become 
addicted to it’. (24-year old Male user)
Emerging evidence has suggested that synthetic 
cannabinoids are highly addictive and have the potential to 
lead to drug dependency. Addiction to Spice has recently 
been identified as a key reason for the high levels of 
consumption in prisons, with some prisoners describing how 
their patterns of use were habitual ‘… like a crack addiction’ 
(RAPt 2015: 4). Furthermore, Baker (2015) reported that 20 
per cent of his sample of male prisoners perceived themselves 
to be addicted to synthetic cannabinoids.
In line with the findings of Every-Palmer (2011) and 
Zimmerman et al. (2009), synthetic cannabinoids were 
perceived to be more psychologically and physically addictive 
than other substances. Throughout the research, many 
drug dependent users of Spice with considerable lifetime 
experience of heroin, crack cocaine, and a range of other 
recreational drugs consistently referred to Spice as being 
more addictive, and resulting in more acute withdrawals 
than other substances they had been dependent on. Indeed, 
ex-dependent heroin and crack users unanimously referred 
to Spice as the most addictive substance, with the most 
acute withdrawals and ‘rattle’, that they had ever taken. 
‘If it can overpower methadone and stop your 
withdrawal from methadone, it shows you that it’s a 
powerful fucking drug’. (35-year old Male, ex-heroin user, 
Approved Premises) 
‘I was addicted, very addicted, I was bad. It was hard 
to get out of, really hard. It’s the hardest thing I’ve ever 
had to do. … Spice is definitely the most addictive 
[substance]’. (27-year old Male, ex-Heroin and Crack User, 
Approved Premises) 
‘Crack heads and heroin addicts have come off crack and 
heroin to smoke Spice, and now they can’t stop smoking 
Spice’. (18-year old Male, Supported Housing)
‘I was smoking it for about 12 months, 18 months. I used 
to smoke all day every day, and I used to spew up all the 
time. I lost a lot of weight. I looked like a crack-head, like a 
full on crack-head. … I could just feel my body completely 
like spewing up pure green chemicals. It was just like toxic 
waste.’ (24-year old Male, Homeless)
‘I’m addicted to Annihilation [a synthetic cannabinoid], I’ll 
go through a gram a day, it’s stronger than any other drug 
I’ve ever taken. [INT: When you say you’re addicted, what 
do you mean?] I get sick, sweaty, hot and cold shivers, 
as soon as I wake up. If I have some, say midnight, as 
soon as you wake up in the morning, straight away, I’ve 
got to have it, to sort me right out [INT: How does the 
addictiveness compare to other drugs?] I’m an ex-heroin 
user and the feelings are the same, you get no sleep, 
hot and cold sweats, spewing up, diarrhea, it’s horrible.’ 
(30-year old Male, Homeless)
Many staff who work closely with users of synthetic 
cannabinoids also drew parallels with heroin or crack: 
‘I see this drug as almost a comparison to heroin, in the 
way of it’s affecting people’. (Supported Housing Staff) 
‘Some are aligning it to heroin withdrawals, so the flu 
like symptoms, the stomach cramps, the sweating, the 
irritability’. (Homeless Day Centre Manager)
Yet despite the strength of synthetic cannabinoids – often 
stated to be 50 to 100 times stronger than even ‘skunk’ 
forms of cannabis – many Spice users reported building up 
high levels of tolerance, with some reportedly using up to 
between five and eight grams a day. 
‘I first started at half a gram [a day], and I’d probably 
get about 30 spliffs out of it in prison. … [Now with] the 
tolerance, I’m up to smoking seven grams’. (Male, 20’s, 
Supported Housing) 
‘When I started smoking it, I only had to put a little bit in it. 
… [But] by the time I was coming off it, I was putting half 
a gram in a spliff’. (23-year old Male, Young People’s drop 
in, ex-Spice user)
As we discuss in section 3.5.6, finding the funds to pay 
for their daily consumption of synthetic cannabinoids led 
many users to commit crime. Indeed, as users’ tolerance 
increased, many found themselves spending up to £50 a day; 
an amount that they would have previously used to fund a 
heroin or crack addiction. The recent doubling in price of 
synthetic cannabinoids, as a result of the implementation of 
the Psychoactive Substances Act  (see section 3.11), will no 
doubt lead to an increase in the types of criminality we outline 
in section 3.5.6. Alternatively, given the increase in price we 
may see a shift to other drugs such as heroin amongst this user 
group and the possibility of a new generation of young 
heroin users emerging. 
Daily use was common with many users reporting using 
to prevent unpleasant side effects which they attributed to 
withdrawal symptoms. These typically included: problems 
with sleep; excessive sweats; loss of appetite; hallucinations 
and paranoia; severe stomach cramps; diarrhoea; 
and vomiting. 
‘I have problems sleeping if I don’t smoke it. I can’t sleep at 
all. … you’re proper wide-awake, do you know what I mean? 
Like real wide eyes, it’s horrible, it’s really horrible’. (18-year 
old, Rough Sleeper)
‘You get no sleep. Hot and cold sweats, spewing up, you’ve 
got diarrhoea’. (30-year old Male, Homeless) 
‘It’s horrible. Hallucinations, stomach cramps, shits, being 
sick, can’t eat nothing, paranoia, everything’. (35-year old 
Male, Approved Premises) 
‘Stomach cramps, puking, sweating and hardly sleeping’. 
(Male, late 20’s, Homeless GP Surgery Drop-in)
‘Always sick blood. It’s just because you’ve got nothing 
else in your stomach, that’s all it is, your stomach lining’. 
(18-year old Male, Supported Housing Focus Group)
‘I’ve bent over like that, and literally, my body just shut 
down. I couldn’t move. I could only move my eyes for 
about half an hour’. (22-year old Male, Supported Housing 
Focus Group)
‘It messes with your cognitive functions and like your motor 
skills, actually moving’. (Male, 20’s, Supported Housing) 
For many users, the quick build-up of tolerance, coupled 
with the acute effects of withdrawal symptoms, led quickly 
to dependency. Indeed, the need to use to feel well, and the 
cravings to use, were comparable to the narratives of heroin 
and crack users.
‘It just rules your life. If you’ve not got your Spice, bollocks 
to everything else. Food, what’s in the fridge, nothing 
matters in the world’. (Male, 20’s, Supported Housing)
An interestingly finding to emerge from the Homeless 
Link Survey is that, when those who had taken NPS in the 
preceding 12 months were asked to identify what single area 
NPS had negatively impacted upon the most, just over a 
quarter (27 per cent, n=9) identified relationships. Only 24 
per cent (n=8) identified their physical health. This is in direct 
contrast with the evidence from the qualitative interviews 
here, with users repeatedly emphasising the highly addictive 
nature of NPS (primarily synthetic cannabinoids) and the 
impact they have upon their physical health. Bearing in mind 
the fact that around four fifths (79 per cent, n=33) of those 
who had used NPS in the preceding 12 months claimed to 
be using NPS at least 5 days a week, combined with the 
qualitative findings we report in sections 3.5.3, 3.5.4 and 
3.5.6, it is noteworthy that only around half of the NPS users 
(51 per cent, n=20) perceived themselves as having a drug 
problem. Moreover, of those who self-identified as having a 
drug problem, nearly two thirds (65 per cent, n=13) were not 
receiving any type of support/treatment to help them with 
their drug problems, despite wanting the help. We discuss 
the reasons for lack of service engagement in section 3.8.
Bearing in mind the addiction and dependence outlined 
above, it is perhaps unsurprising that deaths involving 
NPS often make the headlines, heightening the public’s 
perception of NPS as potentially life threatening. However, 
official statistics on drug deaths present a different picture. 
Between 2004 and 2013, there were 76 deaths involving 
any NPS not controlled under the Misuse of Drugs Act (ONS 
2016). While in recent years NPS-related fatalities have 
increased – with a rise from seven NPS-related deaths in 
2011 to 18 in 2014 (ONS 2016) – over the same period, 
there were more than 100 times as many deaths involving 
heroin or morphine (7,748) and more than 20 times as many 
deaths involving cocaine (1,752) (ONS, 2016). In contrast 
to national NPS-related deaths statistics, the research 
revealed many examples of NPS-related deaths perceived to 
involve synthetic cannabinoids, with almost all users within 
the homeless and supported housing communities able to 
recount at least one person they had known whose death 
they attributed to synthetic cannabinoid use.
‘I’ve seen two people die off it … from having a fit through 
Spice, and them not being able to come out the fit’. 
(Male, mid 20’s, Homeless day centre drop-in, Synthetic 
Cannabinoid Dealer)
‘I’ve had people die in my house on it [synthetic 
cannabinoids]’. (Male, 20’s, Homeless GP surgery drop-in) 
‘I’ve seen three people die off this stuff’. 
(Male interviewed in a City Centre Headshop)
‘I’ve actually seen someone die. Police were 
zapping him, trying to get him back to life’. (18-year old 
Female, Homeless)
‘My mate died in front of me on it’. (23-year old 
Male, Homeless)
‘I watched about five people die off that [Vertex]’. (18-year 
old Male, Supported Housing Focus Group)
3.5.4 ‘It’s mad, proper crazy’: NPS 
use and mental health 
‘I think mental health problems and NPS usage go hand in 
hand, definitely. If you haven’t got mental health problems 
then you probably will do after smoking  spice’. (Homeless 
Charity Coordinator)
There is currently only limited international research (Barratt 
et al., 2013; Bebarta et al., 2012; Castellanos et al., 2011; 
Every-Palmer 2011; Harris & Brown, 2012; Hurst et al., 2011; 
Thomas et al., 2012; Van der Veer 2011; Zimmerman et al., 
2009) on the negative impact of synthetic cannabinoid use 
on users’ mental health. However, given that high levels 
of substance use dependency, mental health illnesses and 
dual diagnosis are prevalent amongst those in the homeless 
community and the adult prison population, the high levels 
of synthetic cannabinoid use reported in this research within 
these groups is particularly concerning. A Home Office review 
of NPS identified a range of negative psychopharmacological 
effects associated with synthetic cannabinoids including 
anxiety, severe depression, self-harm, paranoia and 
psychosis (Home Office, 2014). Our findings support this, 
with users attributing a variety of mental health effects  
to their use of synthetic cannabinoids. 
‘As soon as you become addicted to it, your brain goes 
completely fucked’. (24-year old Male, Rough sleeper, 
Young people’s homeless drop-in)
‘I started hearing voices. … I thought I could send messages 
and that through my own mind without speaking, 
it was horrible, … I went off my head’. (30-year old 
Male, Homeless)
‘Anxiety, depression, anger. … I don’t think I had anxiety 
before smoking Spice me, I really don’t’. (22-year old Male, 
Supported Housing Focus Group)
‘Heavy bouts of psychosis and depression, crippling 
depression. … It’s mad, proper crazy, like a whole different 
dimension’. (Male, mid 20’s, Supported Housing)
‘After about half an hour [after using], that’s what you’re 
left with, just a real acute does of paranoia’. (Male, late 30s, 
ex-user of ‘Spice’ and weekly user of ‘Ice’n’berg’)
‘You may as well just get a syringe of paranoia and whack 
it in your vein. That’s what I felt like after a couple of drags 
of Spice’. (Male, late 30s, city centre headshop) 
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Those users we interviewed that disclosed existing mental 
health problems prior to using synthetic cannabinoids, 
consistently acknowledged that their use of synthetic 
cannabinoids intensified these issues. 
‘I’ve got mental health problems anyway, previous to the 
Spice, but the Spice has amplified them’. (24-year old 
Male, Homeless)
‘I’ve got paranoia and anxiety [anyway] but it [Spice] makes 
it a lot worse’. (22-year old Male, Supported Housing 
Focus Group)
Recent reports from the Inspectorate of Prisons for England 
and Wales (HMIP 2014, 2015) and the Ministry of Justice 
(2016b) have all linked the rise in self-harm and suicides in 
custodial settings with an increase in the consumption of 
synthetic cannabinoids. Our findings provide further support 
for this association. Users often described episodes of 
self-harming or suicidal thoughts after consuming 
synthetic cannabinoids.
‘I’ve had a few episodes where I’ve hurt myself, 
self-harmed and that’. (24-year old Male, Rough Sleeper, 
Young people’s homeless drop-in) 
‘I slashed all my arms because of it’. (30-year old 
Male, Homeless)
‘I could feel my head going. I was getting quite concerned. I 
was self-harming’. (27-year old Male, Approved Premises) 
‘If you don’t have a spliff of it [Spice], it can make you 
think in your head that you want to commit suicide. … 
I’ve gone to jump off bridges and everything’. 
(Female, 20s, Young people’s homeless drop-in)
‘Really vivid thoughts, suicidal thoughts’. (Male, 20’s, 
Supported Housing) 
It is important to note that many of the people we interviewed 
are living in conditions that are likely to lead to poor mental 
health or to exacerbate existing mental health conditions. 
The same can be said for those using synthetic cannabinoids 
in custodial settings. Nevertheless, as we noted earlier, some 
international studies have started to evidence the capability 
of synthetic cannabinoids to initiate mental health issues in 
otherwise healthy young adults (see Castellanos et al., 2011). 
3.5.5 Mental health support needs 
Despite the high usage rates, the evidence of chronic 
addiction and dependency, and the negative physical and 
mental health effects of synthetic cannabinoid use, only 
a small minority of those we interviewed were engaged 
with any kind of mental health or substance use treatment 
services. This finding was supported by the survey of 
individuals engaged with Homeless Link (see section 3.5). 
Out of the 33 respondents who claimed to have used NPS 
at least five days a week for the previous 12 months, only 
seven were receiving support/treatment to help them with 
their substance use. 
Bearing in mind the negative impact of synthetic cannabinoid 
use described above, it is concerning very few of the users 
that we interviewed for this research were accessing 
any form of support or treatment at the time they were 
interviewed. As we illustrate below, several had tried but 
waiting times had deterred them from accessing support. 
These experiences had put others off from trying to access 
support. However, the difficulty in accessing mental health 
support services is not restricted to those with problematic 
substance use. Indeed, the recent Mental Health Lightning 
Review from the Children’s Commissioner (2016) found that 
many young people are unable to access the mental health 
services and support they need. Nonetheless, as highlighted 
in the previous section, given the high levels of substance 
use dependency, mental health illnesses and dual diagnosis 
amongst those in the homeless community, the inability of 
this particular group to access timely mental health support 
is particularly concerning.
‘I’m suffering from PTSD, anxiety, depression, severe 
depression and I’m still waiting for a full mental health 
assessment. I’ve been waiting for a couple of years [now]’. 
(24-year old Male, Homeless)
‘I’m waiting for referrals, all these referrals! I’ve got an 
appointment on the 11th, and I’m like “Yes!” because I’ve 
been waiting ages for it. I’ve been waiting since I was 16 … 
and I’m 19 soon and it’s only just coming through’. (18-year 
old Female, Rough Sleeper)
The length of time it takes to access mental health 
support services in Manchester was also commented on 
by a number of practitioners and staff from substance use 
support agencies.
‘[INT: Do you send people to [mental health support 
agency]?] No, because it takes 6 months to get on the 
waiting list’. (Support worker for Young Homeless)
‘The waiting list is months and months long. … The waiting 
list at [mental health support agency] is fairly prohibiting’. 
(City Centre GP)
The difficulties around accessing mental health provision 
for NPS users is exacerbated by mental health services’ 
apparent reluctance to engage with those NPS users who 
are exhibiting mental health problems as a result of their 
substance use. 
‘Mental health look at it as a drug problem and not a mental 
health problem. … Patients are presenting with mental 
health symptoms as a result of drug misuse, … and then 
you get this half an hour assessment and told to go on your 
way to drugs services. I think that’s the depressing thing 
that will emerge. There will be people with loads of mental 
health problems as a consequence of this [NPS], and no 
one will see it as their role’. (City Centre GP)
‘The homeless mental health team that comes here, 
that is commissioned, … If you’ve got diagnosed with 
schizophrenia and starting to use substances, fine. But if 
you’re one of these young people, … the classic individual 
who had a diagnosis of ADHD during childhood, and been 
lobbed from services, [but is] now taking legal highs, you 
don’t get a mental health service, nobody is interested’. 
(City Centre GP)
These comments are at odds with information we received 
from out-patient psychiatry, community mental health teams 
and acute home treatment teams who were consistent 
in stating that they will not reject a service user due to 
their substance misuse alone. In light of the disparity of 
stakeholder’s views in relation to the current level of mental 
health service support for substance users, we suggest a 
review of existing channels of communication and referral 
pathways (for further discussion see sections 4.2.3, 4.2.4 
and 4.2.5). 
In consideration of the findings presented here in relation 
to drug dependency and perceived addiction, mental and 
physical health effects, and several deaths that were widely 
attributed to synthetic cannabinoids, we suggest a need for 
improved recording, greater public health surveillance and 
awareness, targeted public health messaging and service 
innovation (see sections 4.1 and 4.2). 
3.5.6 Scary Spice? The relationship 
between synthetic cannabinoid use, 
crime and disorder 
‘I got a lad inside and he got [into] £200 debt. And this 
lad had two kids in his pad with two razorblades, and 
obviously if someone’s going to go for your face, you hold 
your hands up. I got to see his arms, all his arms and all 
his face, he’s got a cut from his eye right down to his chin, 
for £200 worth of Spice’. (18-year old Male, Supported 
Housing Focus Group)
Since 2012, Her Majesties Inspectorate of Prisons annual 
reports (HMIP 2014, 2015) have consistently identified a 
causal link between NPS consumption and an unprecedented 
increase in serious assaults in adult male prisons.
‘The increase in the use of new psychoactive substances 
was a significant factor in the increase in violent incidents 
in many prisons – either directly as a result of prisoners 
being under the influence of these drugs or in increased 
bullying due to drug debts’. (HMIP, 2015: 34)
In addition, the Ministry of Justice recorded a 36 per cent 
increase (from 3,640 to 4,963 incidents) in violence against 
staff between 2015 and 2016, which they primarily attribute 
to NPS use (Ministry of Justice, 2016b). 
Although research is now starting to further investigate 
the relationship between NPS use and violence within 
adult prisons (see, for example, Ralphs et al., 2016), there 
is currently a gap in existing knowledge regarding the 
relationship between NPS use and offending behaviour 
in the community. Does NPS use lead to increased levels 
of violence and/or criminal behavior, such as robbery or 
acquisitive crime? The findings from this research would 
suggest that it does, particularly in relation to the use of 
synthetic cannabinoids and the homeless community in 
Manchester. The incidents recounted to the research team 
included: violent behaviour and physical assaults; sexual 
assault and sexual exploitation; and robbery and acquisitive 
crime. Each of these will now be discussed in turn.
Users of synthetic cannabinoids often recalled witnessing 
changes in personality that they attributed solely to 
problematic NPS use. Furthermore, a range of staff from 
services and agencies that are in daily contact with regular 
users of synthetic cannabinoids repeatedly discussed seeing 
users’ personalities change from passive to aggressive as a 
result of their NPS use. 
‘A lot of people have been turning more violent and 
aggressive. … I know plenty of people who have lost 
their temper through it’. (Male, 20’s, Homeless GP Surgery 
Drop-in)
‘One particular client, he really changed, … made some 
awful threats to staff. … And he wasn’t like that normally. I 
think he used spice for about five to six weeks, and in that 
period he just really changed his personality’. (Supported 
Housing Manager)
‘We get people who previously were really passive ending 
up being aggressive’. (Young Homeless Support Worker)
‘People can get very aggressive on it. I don’t know if you 
saw the lad shouting in the centre earlier. Generally he can 
be alright, but he isn’t when he’s smoked Spice, he can 
become quite shouty and quite aggressive’. (Homeless Day 
Centre Manager)
In addition to the changes in personality, many of those 
interviewed also discussed how quickly they, or users they 
knew, would get aggressive and violent if they were unable 
to obtain any synthetic cannabinoids. This ranged from 
threats against shop staff who sold NPS through to violent 
confrontations between users. Indeed, the research team 
witnessed several violent incidents whilst attending city 
centre drop-ins. 
‘You see them all here now, very personable, polite. Just 
wait until they don’t get what they want or we are out 
of stock and they switch instantly. You can see it in 
their eyes, they become all aggressive’. (City Centre 
Headshop Staff)
Case Study 3: Tom
Tom is a 24-year old male. He is currently homeless 
and sleeping rough in Manchester. He is addicted 
to synthetic cannabinoids, having started smoking it 
three years ago whilst in prison, “because it … helped 
me to get to sleep in there”. He claims to suffer from 
numerous mental health problems; PTSD, anxiety, 
severe depression and possible Asperger syndrome, 
which, he says, he “had previous to the Spice, but the 
Spice has kind of amplified them”. Tom has sought help 
to come off the substance but says there is nothing 
available, “they don’t know what to do with you … so 
you get passed round from pillar to post in circles”. 
Substance Use and Addictive Behaviours (SUAB) Research Group  |  3534  |  New psychoactive substance use in Manchester: Prevalence, nature, challenges and responses
homeless community in Manchester, with specific concerns 
raised around the vulnerability and safeguarding of a small 
number of young female homeless users. We now turn our 
attention to the impact that synthetic cannabinoids and other 
NPS are having on a range of supported accommodation, 
including emergency shelter, hostels, bed and breakfast, 
supported housing and approved premises. 
3.6 Taking the strain: The impact 
of NPS use on services within 
Manchester
‘Look at the cost of NPS. If you did … the costs all the way 
through from the various different interventions it would 
be thousands, absolutely thousands of pounds, … from one 
person’. (Prison and Probation Worker)
This section highlights the impact that the high prevalence of 
NPS is having on services and agencies within Manchester. 
In particular, it illustrates the perspectives of those policing 
in the city centre, working for the ambulance service and 
in A&E departments, along with a whole range of services/
agencies that currently find themselves working with NPS 
users – including, for example, prisons, probation, day 
centres, hostels, supported housing and approved premises. 
Throughout the research, staff that we interviewed were keen 
to highlight the problems that NPS use is causing within 
their service/agency. Problems that are exacerbated by the 
physical effects of NPS, such as fitting, respiratory problems, 
vomiting, losing control of bowel functions, etc. (see section 
3.5.3 on effects). In many interviews, staff recalled occasions 
where several users would be experiencing these type of 
effects concurrently, thus stretching resources to the limit. 
This was particular a concern during the night when staffing 
levels were often reduced. 
‘I manage a large homeless hostel for offenders and the 
level of legal high use is very high. … It causes us all sort of 
issues’. (Supported Housing Manager) 
‘It does have an impact because you have to heavily 
staff various parts of the service. Like the garden for 
example. Whenever them doors are open for a smoke 
break we always have to make sure its heavily staffed 
out there … [because] people just randomly collapse’. 
(Day Centre Manager)
‘It [NPS] causes massive problems. … It’s stretching our 
resources because we’re a really small team … and a lot 
of the time when someone presents and their under the 
influence [of NPS], we have to drop all the other  stuff and 
do that. I mean, we’re overworked as it is’. (Young People’s 
Street Homeless Practitioner)
‘When we’ve got somebody who’s using Spice, they’ll 
often go outside to use it, and because it has such a fast 
hit, we’ll often find them collapsed outside the building. It 
generally takes two staff members to bring them back into 
the building, maintain observation, so it takes a lot of staff 
time, [especially] if you’ve got quite a few people using in 
one day’. (Supported Housing Manager)
‘If you don’t give them [other users] one joint, then ‘bham’ 
straight in your face for no reason’. (18-year old Female, 
Homeless GP surgery drop-in)
‘They’ll be just sat there, literally won’t have even know the 
guy, and they’ll just batter him because he’s got Spice, and 
rob it off him’. (18-year old Female, Homeless)
‘If they’ve not got it, they’ll stab you for it, they’ll batter you 
for it’. (Male, 20’s, Homeless day centre drop-in)
‘They’re slashing people up. That’s how far people are 
willing to go for Spice. … I’ve seen a man get stabbed 
in the neck over a bit of Spice’. (27-year old Male, 
Approved Premises) 
In addition to the violence outlined above, interviewees 
also discussed the risk of sexual assault faced by young 
homeless females whilst under the influence of synthetic 
cannabinoids. Some female interviewees also discussed how 
they exchanged sexual services to fund their use.
‘Once you’ve had Spice, that’s it, you’re vulnerable, because 
you can’t move, you can’t do nothing. Especially for a girl. 
Especially in town, with all them dirty bastards in town. I 
know a few guys who have already done it, took advantage 
of a girl, spiced her up bad’. (Male, 20’s, Homeless day 
centre drop-in)
‘I’ve got to prostitute myself tonight because I owe people 
a lot of money, a lot of money’. (18-year old Female, 
Homeless GP surgery drop-in)
‘I’ve slept with people through it, I had to’. (18-year old 
Female, Homeless) 
With regard to how users fund their daily use of synthetic 
cannabinoids, users and staff from a range of services and 
agencies talked of users committing a variety of acquisitive 
crimes and anti-social behavior in the form of begging. 
‘The majority of people [users] have to commit crimes, 
the others sit down and beg.” (Male, 20’s, Homeless GP 
surgery drop-in) 
‘Begging is a huge thing, that’s how a lot of people fund it’. 
(Supported Housing Manager)
‘They [users] are going and stealing DVDs, games, 
whatever. [Then] going into various places, pubs, getting 
money for it, and then going and getting the product’. (City 
Centre Police Officer)
[INT: So are people committing crime the same way they 
would have done with heroin?] Yeah, yeah. A lot, a lot. 
Shoplifting, car theft, robbing all sorts. I’ve seen people do 
all sorts’. (35-year old Male, Homeless, ex-heroin user)
In addition to the acquisitive crime that often characterises 
the behaviour of those addicted to Class A substances, 
there were frequent accounts of homeless users stealing 
from each other. As highlighted above, although these 
incidents are often violent, perhaps more devastating 
for the homeless community itself is the fact that 
dependent homeless users now appear to be breaking 
unspoken codes that have traditionally existed within the 
homeless community.
‘You’ve either hardly got anyone using it [NPS], or loads. 
Because they all group together, and they all seem to go 
“Ooh, maybe try this” and then you’ve got, say five people, 
you’re having to deal with. … It’s very time consuming, … 
it’s hard work’. (Residential Social Worker)
Staff working in supported accommodation would also 
often report cases of residents becoming violent, with staff 
often attributing residents’ behaviour to the effects of NPS 
(see section 3.5.6). Indeed, the propensity of synthetic 
cannabinoids to make users unpredictable, aggressive and 
violent was reported to such an extent that some services 
and agencies had to withdraw previously offered support.
‘There’s a load of support workers who wouldn’t work 
with anyone at [substance use service] because of them 
smoking Spice and the risk of them turning violent for no 
reason whatsoever’. (Homeless Outreach Volunteer)
‘Quite a few people are scared to go out and do the 
outreach work with them [NPS users]. I know I am. 
That’s why I stopped doing it. I just can’t risk it because. 
… I mean I’ve got two friends who have been assaulted 
and it could have been me on those nights’. (Ex-Homeless 
Outreach Volunteer) 
‘We used to do street kitchens on Piccadilly Gardens, [and] 
one of the reasons we stopped doing that was because of 
how violent it started getting. … There was one incident 
where a woman was knocked unconscious, and a guy … 
was about to jump on her head. It was pretty scary, and 
we all had to stop him obviously. After that we never did 
another one, we didn’t have enough people for that type of 
thing’. (Homeless Charities Coordinator)
We now turn our attention to the other main sector where 
the high prevalence of NPS use, and synthetic cannabinoids 
in particular, is having a detrimental impact: the emergency 
services. The sale and use of NPS in the city centre has 
created a significant resourcing issue for the police and 
the health service, especially the ambulance service and 
hospital A&E departments. In terms of policing, there was 
a general consensus among those we interviewed that NPS-
related incidents in Manchester city centre have increased 
considerably in the last year or two. 
‘It’s dealing with the associated ASB that comes with it, 
the crime that comes with it, the health implications and 
dealing with people who have collapsed, who are suffering 
an episode’. (City Centre Police Officer) 
‘I would say in the last two years there has been a three or 
four-fold increase in the number of incidents related to NPS 
that we see each week’. (City Centre PCSO)
‘I’m just going to use one street as an example. … In this 
specific street, in the entire year, 12 months from 1st 
April 2013 to 31st March 2014, we had 14 incidents. The 
following 12 months from the 1st April 2014 to the 31st 
March 2015 we had 99. The following 12 months [1st April 
2015 to the 31st March 2016] we had 295. … 99 per cent of 
them are to do with NPS and the issues that are coming, 
stemming from them’. (City Centre Police Officer)
‘We [the homeless community] used to stick by each 
other, we used to be literally like “If someone messes 
with you, you got to mess with all of us”. … And now, 
[we’re] literally lifting each other for the Spice’. (18-year old 
Female, Homeless)
‘People do things [now] that they would never have done, 
… like rob off your friends. … And you know you’re leaving 
him sweating tonight because you’re taking it. But I need 
it, either he’s sweating or I’m sweating’. (22-year old Male, 
Supported Housing Focus Group)
‘I get robbed every single night from Spice, my money and 
everything, it’s horrible, it’s really horrible’. (18 year old 
Female, Homeless) 
Case Study 4: Jake
Jake is a 23-year old male and currently homeless. 
His first ‘legal high’ was Salvia, which he took 
whilst in the detox wing of HMP Manchester. He 
had previously been a heavy user of cannabis but 
on leaving prison he started using Spice because it was 
easy to obtain and half the price of cannabis.
Jake believes he became addicted to Spice in the 
course of a single day and after smoking only 2 grams 
of the substance. He reports that on the following day 
he suffered significant withdrawal symptoms; nausea, 
stomach cramps, sweats and cravings. Within 4 days 
he had progressed to consuming over half an ounce of 
Spice a day. The drug turned him into a violent person 
– “if I didn’t have 3 grams for my breakfast, someone’s 
getting hurt… and I’m not that sort of person, I’m not a 
violent person usually”.
Comparing Spice to cannabis, Jake says Spice is “1000 
times stronger” and, while a “spliff of bud chills you 
out, a spliff of Spice knocks you out, … like being hit by 
a truck”. He used the drug for around 18 months and 
says he believes some of the chemicals accumulated in 
his system. He found that over time he began vomiting 
‘green chemicals’ whenever he smoked it. He claims he 
managed to wean himself off Spice by locking himself 
away for 3 days and smoking weed to help cope with 
the withdrawal symptoms, although he admits he still 
has a mental craving for the substance. According to 
Jake, the way to stop people getting into legal highs is 
to legalise cannabis. He states that until that happens, 
there will continue to be “people dying and dying 
and dying”. 
To summarise, the relationship between synthetic 
cannabinoid use and crime and/or disorder, the research 
found clear and consistent evidence to suggest that the 
regular use of, and dependence upon, synthetic cannabinoids 
was directly responsible for a range of problematic behaviours 
ranging from physical assaults and sexual exploitation to 
begging, robbery and shoplifting. The reported prevalence 
of assault and robbery were particularly high within the 
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services. Many services did not systematically record NPS 
use or incidents, and even where we found organisations 
that did, these systems were inconsistent and ad hoc with 
staff themselves admitting a need for improvement. Added 
to this was the fact that some users, for a range of reasons, 
chose to not disclose their NPS use.
‘I don’t know how much it’s getting recorded. Plus, people 
aren’t admitting when they’re on Spice either now … 
because the hostels won’t let you in with it, and people 
won’t give you referrals to housing … job workshops and 
stuff while you’re still smoking it. So people just pretend 
they’re drunk or they’re taking something else’. (Homeless 
Outreach Worker)
‘That’s the one thing we need to kind of keep on top of 
really. … We do [currently] do it, it’s just the frequency of 
how we do it. And you can see how chaotic it is, by the 
time you walk from one end of the hall to the other, you 
have ten things to do. So yeah, it’s just something we need 
to be more proactive about, making sure we record [NPS]’. 
(Day Centre Manager)
As the above quote illustrates, many staff are working in 
chaotic environments. This was something we witnessed 
on numerous occasions during research fieldwork to drop-
ins, GP surgeries, day centres and a range of supported 
accommodation providers. These chaotic conditions are 
intensified when dealing with an NPS-related emergency 
involving psychosis, fitting, overdose, or respiratory 
problems. Hence, whilst we advocate the need for improved 
NPS recording systems, we recognise the necessity to do so 
in a way that does not cause additional burden and strain on 
frontline staff that are already working to full capacity and 
dealing with emergencies.
‘Everyone knows what you’re supposed to do, and how 
it would be handy to have [NPS-related] information 
recorded, but actually trying to get that to be the priority 
of people who make decisions about what goes on their 
systems, … it’s a job of work that people haven’t got the 
time to do’. (DAAT Manager)
‘Data recording is always an issue, especially here because 
this department is very busy. If you introduce any kind of 
new recording you know everyone is very reluctant to do 
it because there’s so much paperwork to do all the time’. 
(MRI Acute Emergency Consultant)
With this in mind, it is clear that the development of more 
robust recording systems in consultation with frontline staff 
are required, with careful consideration being given to how 
this will fit in with their day-to-day roles, and any other data 
recording and monitoring that they have to conduct. This 
offers a particular challenge for police and medical services. 
Nevertheless, the research did find some evidence of 
existing monitoring of NPS prevalence and incidents that 
offer positive signs that developing more accurate data 
collection is possible. For example, a number of supported 
accommodation providers and third sector organisations 
working with the street homeless discussed how they 
currently monitor NPS-related incidents.
The negative effects recounted by users, and staff from 
the range of services/agencies that currently find themselves 
working with NPS users, invariably led to instances where 
ambulances were called and users were taken to A&E. As 
with the increased number of NPS-related incidents that the 
police find themselves dealing with, call outs for ambulances 
have also increased sharply recently, as has the burden on 
A&E departments. 
‘I used to go to hospital about three times a week [as 
a result of NPS use], and that sounds stupid, but three 
times a week’. (18-year old Female, Homeless GP Surgery 
Drop-in)
‘There’s a lot of times I’ve been hospitalised. … I’d be 
smoking it with people, and I’d wake up in an ambulance 
on my own. I’d be told I’d been found on my own in a street 
passed out’. (18-year old Female, Rough Sleeper)
‘I’ve had to call ambulance services a lot more now than I 
used to, say two years ago. … I have to do it weekly now, 
I would say once a week’. (Homeless Outreach Worker)
‘We’ve had to call more ambulances in the last six months 
than we have in over 20 years of the centre being open’. 
(Homeless Day Centre Manager) 
‘Anyone who works in A&E that I speak to, they’re like “It’s 
a massive, massive issue”. We [the police] just have to stick 
them in an ambulance, but they are dealing with it at the 
treatment end’. (City Centre Police Officer)
Yet despite being fully aware of the resource implications of 
repeatedly calling out ambulances, for many frontline staff, it 
is the severity of the harmful effects of NPS, combined with 
the unpredictable nature of these effects (see sections 3.5.3 
and 3.5.4), that results in them calling for an ambulance.
‘I think with NPS … we need to be cautious. I don’t like 
taking up ambulance time because you know they’ve got 
finite resources, but it [NPS] is an unpredictable drug. So, 
for example, I think when people fit, there is guidance by 
the NHS that you wait a certain amount of time, … but if 
someone is fitting and on the NPS, I’m not comfortable 
waiting any time at all because of the unpredictability. 
… Which in a way is unfortunate because it’s a drain on 
the NHS resources’. (Approved Premises Manager)
It is important to note here that the resourcing impact of 
NPS use is not just effecting the police, ambulance services 
and A&E departments. As we outlined in section 3.5.4, the 
research uncovered numerous associations between the use 
of synthetic cannabinoids and mental health issues. The 
fact that ‘nobody saw it coming’ highlights the need for a 
closer monitoring of emerging drug trends, as the following 
interviewee explains. 
‘I think there needs to be reviews annually, at least in terms 
of what the picture is, so that we can keep on top of stuff 
and so that staff can stay informed and that users can stay 
informed and services can stay informed. And ultimately, 
as well, to save lives through prevention, but also to best 
commission future services to best meet needs. And not 
only just the needs of the actual users themselves, but also 
‘If we have to send for an ambulance, we’ve got to do 
an incident report’. (Young People’s Street Homeless 
Support Worker)
‘We’ve got an incident and near miss form, which we 
complete. The person that is immediately involved, a 
member of staff, … they’ll complete the incident and near 
miss form, which is then passed to me, and I need to 
complete my bit within 10 days. And I give an account 
of how we’ve responded to that situation, so “Did we deal 
with it appropriately and have we learned from that?” And 
then I send it off … to a health and safety hub, and they’ll 
monitor incidents’. (Approved Premises Manager)
As we discuss in section 3.4, despite the claim by SIGMA 
that outside of London the fastest growing chemsex scenes 
are in Manchester and Brighton, existing prevalence data 
on the use of NPS as part of chemsex amongst the LGBT 
population in Manchester does not exist. However, it is 
worth noting that, as a result of a recent effort to improve 
monitoring through the LGBT Foundation, the recording of 
NPS is improving with the development of substance use 
screening in sexual health clinics. 
‘We’ve started to change the way we monitor things, and 
we’ve started to ask more about drugs and alcohol as 
part of all of our services really. … We routinely ask the 
person if they’ve injected drugs in the past 12 months, and 
then we ask during the assessment about use of chems 
during sex. And all of that data is being collected and 
evaluated by someone at Public Health England’. (LGBT 
Foundation Manager)
There are also signs that better local identification of 
substance use, such as chemsex, will be available shortly 
as measures have also been put in place at national level 
to improve our understanding of the prevalence of drug 
use among people who use sexual health services. The 
forthcoming Genitourinary Medicine Clinic Activity Dataset 
Version 3 (GUMCAD 3) developed by Public Health England 
is due to include data fields on both alcohol and substance 
use, which should provide better evidence both nationally 
and at individual service level (Sullivan, 2015). 
The under-reporting of NPS use also extends to the National 
Drug Treatment Monitoring System (NDTMS). Our research 
revealed that even when users are accessing services 
there are problems with the existing recording systems. 
For example, NDTMS receives data for adults and young 
people who are accessing structured planned treatment 
interventions i.e. Tier 3 interventions. However, because 
of the focus on Tier 3 interventions, the system currently 
omits data from those treatment providers who deliver non-
structured low threshold interventions. 
‘I’ve had a few people [involved in chemsex] over 
the  last few weeks, where they’ve come in, I’ve spent an 
hour with them, but we’ve not gone through the assessment 
because they’ve not actually wanted to access structured 
appointments and support. They’re just coming in for a little 
bit of advice [INT: How would that be recorded?] I don’t 
think that’s being recorded’. (Substance Use Practitioner)
families, communities, kids and whatever, because we’re 
going to see wider and wider impacts there’. (Prison and 
Probation Practitioner)
As we discuss in sections 4.1 and 4.3, there is potential to 
minimise future unexpected burdens on health and criminal 
justice budgets through the establishment of a (Greater) 
Manchester annual substance use survey  and a local drug 
information system, which combined, would help to identify 
emerging substance use trends. 
3.7 NPS recording and monitoring
‘In terms of tracking something like Spice, it can be very 
difficult’. (A & E Nurse)
So far, we have provided clear evidence from a number of 
sources of the prevalence of NPS use amongst specific sub-
populations in Manchester (see sections 3.2, 3.3, 3.4 and 
3.5). We have also documented above, the impact that NPS 
use is having on services within Manchester, such as day 
centres, housing providers, the police and other emergency 
services. Yet despite this unequivocal evidence of the 
prevalence and impact of NPS in Manchester, the existing 
level of quantifiable data to support this is lacking. In this 
section, we turn our attention to the limitations of existing 
forms of data collection regarding NPS, and the need to 
devise a more robust evidence base. 
According to Corkery (2013), relevant and regularly updated 
data are needed from a range of sources (including, for 
example, emergency departments, ambulance services and 
GP surgeries) to inform how we work within the rapidly 
changing NPS environment, and how we can best respond 
to the issues engendered by problematic NPS use. However, 
there was recognition that the current recording and 
maintenance of routine data about NPS is flawed.
‘Overdoses. There is a box to tick for heroin/opioids and for 
alcohol but NPS? No, I don’t think there is’. (A & E Nurse)
‘It only occurred to me the other week that we don’t actually 
record the information, we don’t code it [NPS use], … it’s 
something we’re not doing’. (City Centre GP)
‘We are very bad at recording data, we need to improve 
on this. It would be so much easier if we were electronic 
but we are not, we still use paper, so unfortunately any 
kind of audit here is a nightmare because you have to 
pull out the notes and go through the notes. … [But] again 
there’s the problem that the doctor might not be recording 
it properly, the patient might not know what they have 
taken, or they might not want to tell us’. (MRI Acute 
Emergency Consultant)
‘The police have been slow on the uptake really. … We don’t 
have a closing code for legal highs … because it will be 
that legal highs have caused something else. So it will get 
recorded under that something else, as opposed to the legal 
high’. (City Centre Police Officer)
The lack of robust systems for recording NPS-related 
incidents was not restricted to medical and criminal justice 
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‘A lot of what we do with young people around NPS use is 
not Tier 3 level intervention so it does not get recorded on 
the NDTMS data’. (Young People’s Substance Use Team) 
It was specifically noted how the structure of the TOPs form, 
particularly questions on offending behaviour, are difficult to 
align with chemsex user profiles.
‘The TOPs form is completely not a tool to be using in a 
Chemsex clinic at all. … The questions on there are not 
relevant to that group. … all the [NDTMS] data is wrong’. 
(Chemsex Substance Use Practitioner) 
Substance use practitioners also highlighted a further 
limitation with the NDTMS data recording system that 
centred around the current structure of the TOPs forms 
(Treatment Outcome Profile). Within the core data set, 
services record drug one, two and three (i.e. primary, 
secondary and tertiary substance used), defined as:
The substance that brought the client into treatment at the 
point of triage/initial assessment, even if they are no longer 
actively using this substance. If a client presents with more 
than one substance the agency is responsible for clinically 
deciding which substance is primary.
As we discuss further in sections 3.8, many users of 
synthetic cannabinoids have previous history of alcohol, 
heroin and crack dependency. As such, for those who do 
engage in treatment, the existing approach of recording that 
includes listing a substance, even if that substance is not 
been actively used, ultimately results in the under-recording 
of NPS use on the TOPs forms. This problem is further 
compounded by polydrug use, particularly when polydrug 
repertoires include a number of different NPS. This causes 
specific difficulties in correctly recording the main types of 
NPS that are commonly used. This is a particular problem 
amongst the chemsex user group. 
‘On the TOPs form, it states your heroin, crack, 
amphetamines, cannabis, and at the bottom is ‘other’, 
and then you’ve got the NPS. But if somebody is using 
three ‘other’ drugs, you can only record one of them. 
I get that with the chemsex cohort, because they use 
methamphetamine, mephedrone and GBL. I put the 
methamphetamine under ‘amphetamine’, but it is in 
the drop-down box under ‘other’. But if I use that for 
methamphetamine I couldn’t put mephedrone. So I put 
methamphetamine under ‘amphetamines’, I put the 
mephedrone in the ‘other’, but then I can’t put GBL. 
So I think there probably is a missing data issue’. 
(Substance Misuse Practitioner working with MSM)
We conclude that in the absence of any immediate signs 
of changes to the NDTMS TOPs forms, routine data 
collection on NPS use outside of the NDTMS ‘other’ category 
is required as current assessment and recording tools do not 
sufficiently monitor the issue. 
It must be remembered, though, that alongside the problems 
with official data recording systems outlined above, there 
coexists the problem of non-disclosure of NPS use by users. 
As highlighted in section 3.8, there is a general lack of 
‘Why would I want to go to a place with druggies?’ (Male, 
early 20s, Homeless) 
‘Do you know what they’re for, them drugs services? To 
give new needles, and I don’t use needles, so why do I 
need to go there?’ (Synthetic Cannabinoid User, Supported 
Housing Focus Group 2)
These views were further supported by professionals working 
with this user group. They discussed how the stigma that is 
associated with treatment services often  acts a barrier to 
engagement amongst NPS users.
‘The services that are already set up, they [NPS users] 
think they’re for the heroin users. They don’t feel like it is 
for NPS’. (Supported Housing Staff, Focus Group)
Moreover, several professionals that we interviewed seemed 
to hold similar outdated understanding and knowledge of 
what treatment services offer and what substances they 
work with.
‘They’re addicted to NPS, so why would they go to 
somewhere that deals with class A drugs. … They don’t 
want to be defined as that kind of drug user’. (Supported 
Housing Manager) 
This separation of their use of NPS and the problematic use 
of traditional drugs such as heroin and crack cocaine is an 
interesting finding. Not least because of the many similarities 
that users recounted between regular, dependent use of 
synthetic cannabinoids and traditional problematic drugs 
such as heroin and crack cocaine (see sections 3.5.3 and 
3.5.6). Despite the clear parallels around physical and mental 
addiction, including acute withdrawals and users reporting 
committing a range of acquisitive crimes to fund their usage, 
the fact that many NPS users distanced themselves from 
the traditional profile of a problematic drug user in need 
of treatment is significant. Added to this, for many users, 
it was the perception that treatment services lacked the 
knowledge base to work with NPS users that deterred them 
from engaging with services. 
‘They’ve got nothing to help you because they don’t know 
what’s in it. … They don’t know anything, they’re fucking 
shit’. (Supported Housing Focus Group)
‘I was in A&E because I was on Vertex Space Cadet … 
[and] they didn’t know nothing about it … [and] they didn’t 
even know where to send me to’. (24-year old Male, rough 
sleeper, Lifeshare) 
‘They [treatment services] don’t know much about 
it. All they know is you need to stop it’. (24-year old 
Male, Homeless)
‘[INT: Have you gone to the GP?] No, because they don’t 
have anything to help you for it. … I’ve heard it off other 
people coming here [doctors], rattling off of Spice and 
they’ve not got no help’. (30-year old Male, Homeless) 
‘[INT: If you wanted to get off it in the future, would 
you go to a drug service for help?] No, because I know 
they don’t really know much about it so I’d probably think 
“Well you’re just wasting my time as much as I’m wasting 
yours”’. (Male, 20s, UMVP)
To summarise our findings on the current prevalence and 
resultant impact on users health and frontline services, we 
found numerous examples of the under reporting of NPS use 
and related incidents and therefore suggest a significant level 
of under reporting currently exists across a range of services. 
As sections 3.5.3 and 3.5.4 have illustrated, many users are 
experiencing a range of physical and mental health issues 
and report addictiveness and dependency, yet their service 
needs are not being met due to client perceptions of what 
services can offer. Furthermore, we have illustrated here 
that even when users do engage with treatment services or 
criminal justice and health agencies, their NPS use is often 
unrecorded. Having noted the lack of user engagement with 
treatment services and the subsequent under reporting of 
NPS use, the following sections explore another key focus 
of the research – the reasons why users are reluctant to 
engage with services.
3.8 NPS use and service user 
engagement 
‘There are people who we’re seeing on the streets a lot, 
young people particularly, who aren’t accessing city 
centre projects and they’re not accessing Lifeshare, they’re 
not going to the Booth Centre, they’re just staying on 
the streets, and begging for money for Spice. … They‘re 
not engaging with any services at all’. (Homeless Case 
Manager at City Centre Medical Practice)
As the above quote above illustrates, there was an 
acknowledgement that many NPS users are not accessing 
the available support on offer. Indeed, throughout the 
research, we found a clear lack of engagement with treatment 
services by many regular NPS users. This was despite the 
acknowledgement by many users that their use of synthetic 
cannabinoids was causing them a range of problems (as 
outlined in sections 3.5.3, 3.5.4 and 3.5.6.). While in section 
3.5.5 we highlighted the unmet mental health needs of many 
users and the need for a more integrated mental health and 
substance use response, in this section we focus on the 
reasons provided by users and frontline staff for the lack of 
engagement with the local substance use treatment services. 
3.8.1 ‘It ain’t crack or smack’: 
The reasons why NPS users are 
not engaging with services 
Despite often raising concerns regarding their NPS use (see 
sections 3.5.3 and 3.5.4 on effects), many users of synthetic 
cannabinoids that we encountered did not perceive their 
drug of choice as serious enough to warrant seeking support 
from either a GP or treatment services. 
‘I can’t go to somebody and say “I’m addicted to Spice”. … 
[They’ll say] “Well Spice is legal so what are you worried 
about?”’ (Male, early 40s, Synthetic Cannabinoid User 
Interviewed in City Centre Headshop)
The stereotypical views that services are just a place for 
injecting heroin and crack cocaine users provided further 
evidence for the need for services to better promote what 
services and support around NPS use they can offer. We 
came across many young NPS users in particular who 
viewed treatment services as a place for heroin and crack 
users or a place to obtain clean needles.
Case Study 5: Dr X
Dr X is an acute consultant in the Accident and 
Emergency Department of a Manchester hospital. He 
tells of numerous problems that the medical services 
experience in trying to deal with the effects of NPS. 
Acute patients may present with serious overdose/
withdrawal symptoms but are unwilling to disclose 
what they have taken as they are afraid of the possible 
legal or social consequences; “They are worried it will 
get to their GPs, it will get to their parents, it will get to 
their work, it will get to social services, they won’t get 
social accommodation, or it will go on the computer and 
be there for years”. This not only makes treating them 
more complicated, but it also hampers the collection of 
accurate data on the situation, which, he says, is already 
a problematic process. 
He noted that the current system does not allow 
for recording specific NPS data as, for these types of 
patients, it only has general categories of ‘intoxication’ 
and ‘collapsed’. Dr X recognises the importance of 
accurate data, but admits that more detailed recording 
would put additional stress on a busy department 
already “plagued by paperwork”. Case records are still 
largely paper-based and he believes a fully computerised 
system would alleviate many problems related to 
workload and information retrieval.
Dr X tells of the difficulties his department experiences 
in referring patients on to other health services. For 
example, he explains that ‘substance use’ and ‘mental 
health’ are completely separate services that “don’t 
talk to each other”, so a patient presenting with severe 
symptoms of psychosis, or ‘spiceophrenia’ as medical 
slang has dubbed this condition, can be refused by both 
services as they are assessed as being more relevant to 
the other. This results in the excessive and inappropriate 
use of acute medical resources and essentially unsuitable 
treatment of the patient. 
A further problem outlined by Dr X, with regard to 
the effects of NPS, is that of staff training. In large 
hospital departments, with a high staff turnover 
and high number of trainees, keeping all relevant 
personnel up to date is very difficult. The symptoms 
of NPS withdrawal or overdose can be non-specific 
and relate to numerous other medical problems, so 
without proper awareness, staff can fail to monitor 
or treat patients appropriately. Better knowledge 
of other services and the creation of a ‘substance 
misuse pathway’ would, he believes, greatly assist 
in improving the overall level of help available to 
these patients. 
reporting of health issues to GPs or treatment services – 
mainly due to a (mis)perception they do not have anything 
to offer. There was also an overall reluctance amongst 
NPS users to disclose NPS use due to the risk of it 
impacting negatively upon license conditions and 
housing tenancy agreements. 
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agonists (CB1 and CB2) as the active ingredient in cannabis 
– delta-9 tetrahydrocannabinol (THC) – the effects bear little 
resemblance to those associated with cannabis. We have 
already outlined the impact of synthetic cannabinoids on the 
mental and physical health of users (see sections 3.5.3 and 
3.5.4). These wide-ranging effects go beyond the symptoms 
and harms that the typical cannabis user would present 
to services with. Indeed, many of the effects discussed 
by synthetic cannabinoid users are more in line with the 
physical effects of heroin or psychological effects of crack 
cocaine. Added to this, is the reported aggression it bestows 
in users. Because of this, many users and stakeholders have 
called for a specific intervention to be developed to serve the 
particular needs of dependent synthetic cannabinoid users.
‘I also think [we need] some kind of specialist service for 
people who are using Spice. … Because it’s not heroin, it’s 
not crack, it’s not cannabis, it’s a drug on its own, and 
people who are using it need to talk about how they feel 
when they’re using it, and the withdrawals, and have that 
support that’s maybe linked into like recovery, to look at the 
reason why they’re addicted to things’.  ( S u p p o r t e d 
Housing Manager)
‘It’s quite hard at the moment because they [users] 
are approaching drugs services and there’s not a lot out 
there to help people through Spice addiction. … There 
needs to be something that’s specific for NPS’. (Supported 
Housing Worker)
‘People are going to need something to come off it, that’s 
what I say. Because it’s not going to go away this, this 
drug, legal high’. (30-year old Male, Homeless Synthetic 
Cannabinoid User)
Despite the acute withdrawal symptoms, we came across a 
handful of users who had managed to cease using synthetic 
cannabinoids without any support from services. For all but 
one, they had relied on smoking as much skunk cannabis 
as they could get hold of and locking themselves away in a 
room with basic provisions.
[INT: If you wanted to get off it, where would you go to, 
would you go to the doctors or services?] Just lock myself 
in my room and keep myself away from it. All you can do’. 
(Daily Synthetic Cannabinoid User, Interviewed in City 
Centre Headshop)
However, it is important to note that not everybody wishing 
to address their synthetic cannabinoid use is in the position 
of being able to ‘lock themselves away’, as this young street 
homeless male observes.
‘You need to be in a position to detox. You need a roof 
over your head for starters. You’re going to be hot, cold, 
sweating, you’re sick, you shit yourself, … you can’t control 
fuck all, you can’t control your bodily functions’. (24-year 
old Male, Homeless)
In addition to the physical symptoms experienced by those 
users trying to cease their synthetic cannabinoid use, some 
users also discussed a deterioration in their mental health 
when they stopped using. 
The perception that treatment services do not know how 
to deal with NPS users was further supported by frontline 
workers, and was often raised during interviews.
‘[Treatment service name] don’t know [how to deal 
with Spice] and they’re the biggest drug service’. (Support 
Worker for Young Street Homeless Project)
‘I’m not entirely sure how much faith I have in any of those 
services in these issues. … I don’t think there are currently 
any agencies that would offer practical help’. (Homeless 
Outreach Worker) 
‘If I go see mental health, mental health says “Oh I don’t 
need to see you, he didn’t take that drug with intention 
of harming himself, he went out and had a good night”, 
and even if they present with signs, clinical signs and 
symptoms of depression they say “As long as he’s taking 
those drugs I can’t assess him”. So we are just passing the 
buck all the time’. (A&E Consultant) 
Added to this is the problem that, even where appropriate 
support services do exist, a number of the users and 
professionals we interviewed were seemingly unaware 
of what services and support are available to NPS users 
in Manchester. 
‘I don’t know who’s available, and what’s available’. 
(30-year old Male, Homeless)
‘It’s hard to know who to refer to at the moment with Spice. 
… There’s no one you could directly refer anyone that uses 
Spice to. Who do you refer to? What can people access? We 
don’t know’. (Supported Housing Manager) 
It is a concern that many of the staff we came across who 
work in services where these hard to engage users with 
complex needs are presenting have such negative views 
of existing substance use provision. If these negative 
views on what is available to NPS users are being 
inadvertently projected onto this hard to engage user group, 
by professionals that they trust, then it clearly makes the 
likelihood of users engaging with services even more remote. 
3.8.2 New substances = new needs = 
new services? 
In section 3.4.4 we discussed the need for specialist 
intervention around chemsex. Likewise, when discussing 
synthetic cannabinoid use, there were similar suggestions 
raised during the research. These included relocating 
NPS support away from traditional treatment services, 
due to stereotypes and fear of stigmatisation, through to 
the development of a specialist service and bespoke NPS 
interventions, including synthetic cannabinoid detox 
provision and NPS-focused staff who would develop 
expertise and hold a caseload of synthetic cannabinoid 
users. We commence this section with a focus on the 
debates around the need for synthetic cannabinoid 
specific treatment provision and how that provision 
might look. 
‘Longest I’ve been without it? A couple of days and I ended 
up going mad’. (Male, early 20s, Synthetic Cannabinoid 
User, Interviewed in City Centre Headshop)
In summary, the views presented here of synthetic 
cannabinoid users and stakeholders would suggest that 
services should consider the development of a community 
based synthetic cannabinoid intervention that included 
detoxification support. However, subsequent discussion 
with current integrated drugs and alcohol service providers 
CGL uncovered existing provision for NPS users, including 
synthetic cannabinoid use. This provision included extended 
brief interventions of six to nine sessions for moderate users 
through to interventions for users with severe dependency, 
including a range of medication to assist with withdrawal. 
GCL are also based across a number of different community 
venues (e.g. libraries). Once again then, we found the need 
for improved marketing and awareness raising of the existing 
offer to both users and stakeholders. We stress that this also 
needs to incorporate a clear referral pathway that includes 
appropriate and accessible mental health provision  (see also 
sections 4.2.3 and 4.2.4). 
3.8.3 The changing profile of injecting 
users 
There are currently clear signs that suggest that an 
unprecedented change is occurring, whereby some of the 
‘traditionally’ most marginalised and vulnerable user groups 
in society, who may previously have been introduced to 
heroin – either whilst serving custodial sentences, or as a 
result of living on the streets – are currently being introduced 
to synthetic cannabinoids instead. The result of this change is 
that, compared to their 1980s, 1990s and 2000s counterparts, 
the problematic drug use of these groups is now much less 
likely to be intravenous heroin use. Alongside this, both 
local and national figures have illustrated a change in the 
‘make-up’ of users of needle exchanges, with approximately 
two-thirds of those accessing needle exchanges being users 
of image and performance enhancing drugs (such as steroids) 
rather than heroin. Furthermore, the emergent chemsex 
scene and the ‘slamming’ of crystal methamphetamine and 
mephedrone has introduced another new user of needle 
exchanges into the mix. As we discussed in section 3.4, this 
change in the profile of injecting substance users’ needs 
to be reflected in the provision of needle exchanges and 
safe injecting information. As we discuss in more detail in 
sections 3.4 and 4.2, these changes in drug using patterns 
at both the local and national clearly warrant consideration 
when it comes to the development of future service delivery 
within Manchester.
3.8.4 Integrating mental health 
support and substance use services
‘Mental health won’t deal with them until they’ve addressed 
their substance misuse’. (Homeless Day Centre Manager)
‘We can’t get a dual diagnosis because they [the mental 
health services] are saying it’s drug-induced psychosis, 
and they [the substance use services] have to deal with 
3.8.2.1 ‘What’s on offer that’s going 
to make people come in?’
One of the most frequently cited factors when it came to 
non-engagement was the perception that treatment services 
lacked the offer of substitute medication. The lack of a 
substitute prescription was particularly cited as an issue by 
users who had previously engaged with services for heroin 
addictions. These users would compare the treatment offer 
for heroin with what they perceived to be on offer for Spice.
‘What’s on offer that’s going to make people come in? 
What’s out there to substitute Spice, treatment wise? … 
Going into treatment as a heroin user, I know I’m not going 
to rattle every day [but] for Spice, there’s not any  of these 
things, so why am I going to get treatment?’ (Male late 
30s, Ex-heroin user, current NPS user)
‘What is there to substitute my Spice? … There’s a vacuum, 
there’s nothing there for me.” (40-year old Male, User of 
‘Ice’n’Berg’)
‘A chemical of some sort [to substitute NPS use] is going 
to get me to treatment because that’s what I know’. (Male, 
late 30s, Ex-service user for heroin and crack, interviewed 
purchasing NPS in a City Centre Headshop)
‘There’s nothing there to get off it. … You can prescribe a 
heroin addict with Subbie [Subutex], … but there’s nothing 
out there [to prescribe to NPS users]’. (23-year old Male, 
Homeless, Synthetic Cannabinoid User)
Interestingly, the lack of any substitute medication to 
replace synthetic cannabinoid dependency was also cited as 
a barrier to treatment engagement by professionals working 
with this user group.
‘For other drugs there’s a clear route. If someone’s using 
heroin or crack, it’s very easy for me because there’s a 
nice route which I can go down, generally by prescribing 
alternatives. But [with NPS] there’s no clear route. … It’s 
generally just to motivate them, to ask people to think 
about their use of legal highs and things like that. … I don’t 
have any route really for someone who is just using legal 
highs’. (Homeless Outreach Worker)
3.8.2.2 ‘There needs to be something 
that’s specific for NPS’
There is an ongoing debate regarding how much services 
need to adapt when working with NPS users. As we noted 
in section 1, most – although by no means all – NPS 
have been developed to mimic the effect of traditional 
substances and fall within traditional broad categories such 
as stimulants, hallucinogens, dissociatives and depressants. 
It is argued by many that the same harm reduction advice, 
motivational interviewing techniques and psychosocial 
interventions, identification of triggers and so forth can be 
applied regardless of the substance involved. While this 
may hold true for some types of NPS, the case of synthetic 
cannabinoids seems to be an exception. Despite synthetic 
cannabinoids being designed to work on the same receptors 
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heart say, I don’t know where we as an organisation are 
with education [around NPS]’. (City Centre Police Officer) 
It was particularly concerning to learn that GPs and A&E 
staff also lacked training and knowledge in relation to how 
to deal with patients that present with NPS use. 
‘[INT: Do you get any specific training around NPS?] No, 
no you don’t. As a new starter, I found myself explaining 
what Spice and NPS and these sorts of legal highs were to 
some of the staff, much more experienced staff than myself. 
And that’s just through having taken an interest in certain 
documentaries, and then coming across it a few times 
myself at the A&E now. … [Although] there’s mandatory 
training that you have to go through [and] some of that 
includes overdose training, it is kind of the general signs 
and symptoms, usually of heroin or alcohol overdoses’. 
(A&E Nurse)
‘If they [the tenant] look under the influence [of NPS] 
we need medical advice before they can [receive their 
medication] and normally the only medical advice 
available is the NHS advice telephone line. [But] they 
really struggle to make decisions because it’s such an 
unpredictable drug, so they’ll … pass it to a nurse, who 
will pass it a doctor, and you can be talking hours before 
you get a response. … A lot of doctors, once it eventually 
gets to a doctor, will feel confident enough to say “Yes 
it’s safe” or “It’s not safe” to take [the medication], … but 
some doctors won’t feel confident or willing to make a 
decision and they’ll say “Tell them to present to A&E” 
or “You take him to A&E”. We’ve had a couple of occasions 
where they’ve said “Ring an ambulance”’. (Approved 
Premises Manager)
In addition to this lack of training for key frontline staff, 
where training around NPS actually had been delivered, the 
research uncovered some clear signs of frustration amongst 
staff from those agencies and organisations who work with 
NPS users on a daily basis. 
‘[Treatment service name] came over here and delivered 
some legal high training, and there was nothing 
new  that they was telling us that I’d not already told 
them’. (Young People’s Street Homeless Project Worker)
‘We have had training on it last year but to be honest I 
didn’t rate it’. (Supported Housing Manager)
It appeared from the interviews we conducted with frontline 
staff that, when it comes to training around NPS, what 
they want are practical tips and good practice on how to 
respond in emergency situations, rather than simply generic 
overviews of NPS.
‘We had some legal highs training … but it was very much 
more about the background and how legal highs came 
about and head shops and stuff like that. … We’re still 
trying to sort some training really to say to staff what’s 
good practice, what we can do, what things you need to 
look out for, work with harm reduction, that’s the kind of 
thing we need’. (Supported Housing Manager, 2)
As highlighted in the above quote, it is clear that training 
needs to move beyond the basic introduction to NPS and 
the drug problem before they [the mental health services] 
deal with the mental health problem’. (Young People’s 
Substance Use Practitioner) 
As these quotes illustrate, one issue that consistently 
featured in our interviews with both NPS users and a broad 
range of professionals was in relation to the current level of 
mental health support available to users of NPS. There was 
a commonly held view that substance use and mental health 
teams need to be much more integrated to enable them to 
better address the many problems and issues (see sections 
3.4.7 and 3.5.4) that arise from the problematic use of NPS, 
in particular synthetic cannabinoids and those substances 
associated with the chemsex scene.
‘Mental health services just do mental health, and drugs 
services just do drugs don’t they? And we know that 
this individual [the user] lies in the middle’. (City Centre 
Medical Practice Homeless Case Manager)
‘The problem with mental health and substance misuse is, 
because of the way services are, the first thing they’ve got 
to do is reduce substance misuse before they’ll do mental 
health work. But they’re both hand in hand’. (Support 
Worker, Young Homeless)
‘I would like to see mental health services work in 
partnership with substance misuse services, to kind of 
have a single point of entry’. (City Centre GP)
‘Substance use and mental health have become completely 
separate services and unfortunately [they] don’t talk to each 
other. … We see this often, … they haven’t got any kind of 
links or anything, and it’s unfortunate because we should 
be working hand in hand’. (A&E Consultant)
While the findings of this research suggest a need to review 
current mental health provision for users of NPS, with a view 
to more integrated mental health and substance use service 
delivery, as we outlined in section 3.4.7 there was also an 
identified need for the integration of mental health and 
counselling support into the current sexual health service 
support for MSM involved in chemsex. However, the Mental 
Health Improvement Programme is clear and encouraging 
evidence that commissioners are seeking to improve and 
transform the current offer. As we discuss later in the report 
(see section 4.2.3), we suggest the necessity to convey 
to stakeholders the new service provision and treatment 
pathways that the recent commissioning of new substance 
use and mental health service providers (CGL and the 
Greater Manchester West Mental Health NHS Foundation 
Trust). This represents a significant stage in an ongoing 
process to ensure Manchester’s Mental Health and Social 
Care Trust is stronger and more sustainable and to improve 
mental health services in Manchester by bringing them more 
closely together with other health and community services. 
Furthermore, there was some emerging evidence that recent 
commissioning to address these concerns was already 
having a positive effect. During the latter stages of data 
collection (April 2016), the newly commissioned Manchester 
integrated alcohol and drug service, delivered by service 
providers Change, Grow, Live (CGL), was introduced. At the 
time of writing, this has already led to a number of positive 
developments between CGL and the Dual Diagnosis Liaison 
focus more on answering the questions that these frontline 
staff are asking, such as ‘At what stage should we call out an 
ambulance?’ Furthermore, it is clear that any training should 
include clear guidance on what is current best practice when 
it comes to working with NPS users.
‘What is the best evidence base for what our approach 
should be for people that are using this stuff? … That’s sort 
of what I’m looking for. We can upskill staff, and we can 
make them aware and that sort of thing, but their ability to 
do something about it, to intervene and make a difference. 
That’s the bit that I really want to see’. (Probation Manager) 
As we have illustrated, keeping up to date with the emerging 
drug trends and how best to respond, clearly presented a 
number of challenges for a range of professions and service 
providers. The production of short, two page key information 
guides was also requested by many practitioners and 
supported accommodation staff that we interviewed.
‘Just signs and symptoms, the things that we can do in 
terms of treatment, the withdrawal side of things, things to 
look out for’. (A&E Nurse)
‘[I’d like an] idiots guide, 2-pages’. (Senior 
Probation Officer)
However, when it comes to actually highlighting best 
practice, or raising awareness of emerging trends and 
developing appropriate training materials, we suggest that 
frontline staff working in day centres, hostels, supported 
housing, approved premises and prisons have much to offer. 
The research team found many examples of knowledge and 
expertise amongst these frontline staff because of the high 
volume of NPS users and incidents that they are dealing 
with on a daily basis. This knowledge has the potential to 
be shared and utilised more widely, including by substance 
use workers and medical staff (e.g. GPs, emergency services 
and A&E doctors and nurses). For example, it was typical for 
substance use practitioners (in both adult and young people’s 
services) to note that they only have one or two NPS users 
on their caseloads. In contrast, as we evidence throughout 
the report, many of the agencies and organisations who 
are in daily contact with users have accumulated a wealth 
of experience. 
‘It’s just one of the recognisable signs [of NPS]. … If they’re 
coming in frothing at the mouth, you know for a fact 
[they’ve taken it]’. (Lifeshare Support Worker)
‘One of the things that I found quite helpful when dealing 
with people on Spice was just to sit them up, give them 
some water and just say “Look”, try and just make them 
focus on where they are and who they are and the fact that 
they’re going to be okay’. (Homeless Worker)
‘We’ve learnt loads. We’ve learnt not to react too fast to it 
because people can come out of it within 5-10 minutes, 
so we’ve learnt to observe people when they’re under the 
influence of it, just make them safe. We tend to lay them on 
their side as well in case they do vomit, and then just keep 
regular checks on them. … Then if we do become concerned, 
or they don’t seem to be coming out of it, then we’ll contact 
the ambulance’. (Supported Housing Manager)
Service who are part of the Manchester Mental Health Social 
Care Trust (MMHSCT). A central remit of the Dual Diagnosis 
Liaison Service is to facilitate mental health and substance 
misuse services working in a more integrated way. Although 
the new integrated alcohol and drug service providers were 
only recently in post, the new structure had already led to 
positive signs in the development of an improved model of 
joint working between mental health and substance misuse 
services. Incorporated in to this is an ongoing programme 
of Dual Diagnosis Liaison Service led training to 80 CGL 
staff that focuses on (i) mental health services information 
and pathways (ii) CBT for psychosis, anxiety, depression (iii) 
CBT and schema based work for personality disorder and (iv) 
risk and crisis. The Dual Diagnosis Liaison Service and CGL 
have also conducted a review of dual diagnosis pathways. 
This comprises the development of revised guidance on 
impatient Dual Diagnosis Referrals to the Manchester 
integrated alcohol and drug service. These care pathways 
clearly illustrate the pathway of a CGL client into MMHSCT 
and the pathway of a MMHSCT client into CGL’s integrated 
alcohol and drug service. Other noteworthy developments 
in partnership working have included the encouragement 
of MMHSCT and CGL staff to attend each other’s meetings 
and visit bases in order to facilitate more awareness and 
strengthen the integrated drugs and alcohol and mental 
health trust working partnership.
Nevertheless, the regular reporting of mental health 
concerns linked to NPS that cut across vulnerable groups 
using synthetic cannabinoids, students, clubbers and 
chemsex users suggests that the potential need for further 
innovation and efficiency in the use of resources to address 
the mental health implications of NPS use. The reports of 
lengthy waiting times for assessments are something to 
monitor and review. The Dual Diagnosis Liaison Service 
is currently staffed by two clinical nurses and presently 
operates as a non-urgent service with appointment dates 
within 28 days. Existing guidance incorporates quarterly 
reviews of mental health service response and appointment 
times. We suggest that the commissioning of new mental 
health service providers (Greater Manchester West Mental 
Health NHS Foundation Trust) that commences in January 
2017 offers an ideal opportunity to review appointment times 
and existing dual diagnosis staff provision.
3.9 Training and knowledge
The research identified a clear training need for frontline 
staff working with NPS users. Indeed, the lack of routine 
training around NPS amongst some services was particularly 
surprising. This training need was further evidenced by 
many of the staff we interviewed during the course of the 
research actually asking the research team for information 
and training. 
‘I was offered one training course about a month ago 
… but that’s all really. … I think there needs to be an 
ongoing training programme offered to agencies’. 
(Homeless Outreach Worker)
‘[INT: Have police officers received training on how to deal 
with NPS?] No, there is no training. … I’ll honestly hand on 
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as a Greater Manchester LDIS rather that solely serving 
Manchester. This suggestion had the support of many 
stakeholders we interviewed.
‘It just doesn’t make any sense not to have that [a LDIS] 
for Greater Manchester linked to an early warning system’. 
(DAAT Manager) 
‘I think early warning systems are great networks for people 
to get the right information written in a concise way. … 
I think there should be regional early warning systems in 
place’. (Homeless Day Centre Manager) 
The LDIS model proposed by Mike Linnell for Public Health 
England pulls together elements from the Salford model and 
other areas and is intended to complement existing Public 
Health England protocols used to assess intelligence, issue 
briefings and alerts. It is intended to respond to immediate 
risk, to be a low-cost, low-maintenance and multidisciplinary 
system that uses existing local expertise and resources 
(Public Health England, 2016). The Public Health England 
guidance sets out an ambition for an England-wide 
network of local systems that operate in a consistent and 
complementary way. We propose that Greater Manchester 
has an opportunity to be at the forefront and champion of 
this ambition by developing a LDIS that incorporates the 10 
Greater Manchester boroughs. 
Prior to outlining our full set of recommendations, we first 
turn our attention to the impact of the recently introduced 
Psychoactive Substances Act. 
3.11 Impact of the Psychoative 
Substances Act 2016
During the course of this research – 26th May 2016 – the 
Psychoactive Substances Act 2016 was introduced. The 
Act represents the most significant legislative change 
in NPS focused UK drug policy since the banning of 
mephedrone and related synthetic cathinones in March 
2010 and the subsequent introduction of temporary class 
drug orders (TCDOs) in 2012. In summary, the Psychoactive 
Substances Act makes it an offence to produce or supply 
any psychoactive substance, if the substance is likely to be 
used for its psychoactive effects. The only exemptions from 
the Act are those substances already controlled by the 1971 
Misuse of Drugs Act, nicotine, alcohol, caffeine and medicinal 
products. Possession of a psychoactive substance is not an 
offence (except in a custodial institution), but possession 
with intent to supply, importing or exporting a psychoactive 
substance are all offences. In essence, the Psychoactive 
Substances Act aims to shut down all UK-based shops and 
websites that trade in psychoactive substances.
3.11.1 What impact is the Act likely 
to have in a local context?
The Act was devised with the intention to reduce overall 
availability of NPS, and ultimately use. However, evidence 
from Ireland and Poland (that both introduced a blanket 
NPS ban in 2010) suggests that such legislation does not in 
There is an obvious need for this firsthand experience and 
learning to be shared as best practice. We strongly believe 
that the knowledge that frontline staff have accumulated 
should be used to inform and develop better training for 
those who find themselves working with NPS users, 
including medical staff (e.g. paramedics, A&E doctors and 
nurses). As we outline in more detail in section 4.1, we 
propose the setting up of a local drug information system 
as outlined in recent Public Health England guidance 
(see Public Health England 2016a; Linnell, 2013). Not only 
will this help to facilitate this knowledge exchange, it will 
also go some way to making staff in frontline services feel 
less isolated and more confident when it comes to dealing 
with NPS. 
3.10 Developing a Greater Manchester 
local drug information System (LDIS)
‘I think for all the boroughs in Greater Manchester to come 
together and have a strategy in terms of managing our 
drug services to feel equipped in dealing with the problem. 
I think there’s a bit of fear of the unknown for drug services 
in terms of managing it so basically something that will 
increase confidence for people that are working with 
individuals to feel that they are armed to address the issue 
and it not being this unknown kind of panic’. (Homeless 
Day Centre Manager)
As the previous section has highlighted, professionals 
working with these user groups identified gaps in knowledge, 
isolation, and a lack of clarity regarding best practice and 
referral pathways. Others expressed concerns that they were 
unsure if they were doing the right thing when dealing with 
somebody under the influence of NPS. In particular, a lack 
of clear guidance and pathways were discussed. In January 
2016, Public Health England produced detailed guidance 
for local authorities, including systems and approaches 
for establishing a local drug information system (hereafter 
referred to as ‘LDIS’). As we go to recommend in section 
4.1, we believe that the establishment of a LDIS that uses 
consistent and efficient processes for sharing and assessing 
information, and issuing warnings where necessary, can 
help ensure good, effective information quickly reaches the 
right people (Public Health England, 2016).
The establishment of a LDIS, to facilitate the sharing of 
information on NPS within and between services through 
a more formal network, would help to overcome many of 
the concerns we have identified in the preceding section. 
During the course of the research we learnt of many ways 
that frontline staff have developed skills in how to deal with 
users of NPS (see section 3.9). A central function of a LDIS 
is to inform professionals and frontline staff. Establishing 
a LDIS would facilitate the sharing of this type of shared 
learning that would serve to increase staff knowledge and 
competency across a range of professions that we note 
are affected by NPS use (see section 3.6). As section 3.7 
illustrates, there is a clear need to improve local recording 
and intelligence and a LDIS would provide a hub to share 
and develop this evidence base. This in turn, will enable a 
more effective response.
fact reduce prevalence. Rather, the blanket ban has simply 
shifted the trade in NPS to the illegal drug market and the 
unregulated online market (European Commission 2014). 
In the case of mephedrone, that was banned in the UK in 
2010, the ban simply shifted the market to the illegal drug 
market, resulting in the price increasing from £10 to £20 per 
gram (DrugScope Street Drug Survey 2011), while having 
a negligible impact on prevalence. For example, research 
conducted in two ‘gay friendly’ London clubs in 2013 found 
that mephedrone was still reported as the drug of choice 
with 60 per cent of survey respondents reporting using it on 
the night (Moore et al., 2013). 
In our survey of clubbers (see section 3.3), we asked about 
their motivations for using NPS. The top three responses 
were because they were cheaper (24 per cent), available 
online and in shops (19 per cent) and because they were 
not illegal to be in possession of them (15 per cent). If we 
take the example of mephedrone in 2010, we witnessed a 
doubling in price from an average of £10 per gram to £20 
per gram. Early indications from users in Manchester are 
that synthetic cannabinoids have already doubled in price 
since the Act was introduced. This anticipated hike in prices 
coupled with the reduction in availability of some NPS from 
headshops and online sellers, we believe will lead to a 
decrease in the use of some NPS that mimic the effects of 
cocaine, amphetamines and ketamine and MDMA. However, 
the main NPS used in our survey of clubbers – ketamine 
(2009), mephedrone (2010) – have long since been controlled 
under the Misuses of Drugs Act. The high reported levels 
of past month use of these drugs is clear indication that 
they continue to be widely available on the illegal market. 
A similar picture exists with the other NPS associated with 
chemsex. In addition to the use of ketamine and mephedrone, 
the use of crystal methamphetamine and GHB/GBL are the 
other main drugs in this scene. Crystal methamphetamine 
has been a Class A drug since 2007 and will therefore not 
be affected by the Act. Both types of ‘G’ (GBL and GHB) 
can be used legitimately as industrial solvent and paint 
stripper-type chemicals. Since GHB was classified as a Class 
C substance in 2009, GBL has largely taken over, as it is 
more readily available to purchase as an industrial cleaner. 
In summary, it is envisaged that the use and availability 
of the most popular used NPS amongst students (nitrous 
oxide) and clubbers (ketamine and mephedrone) and MSM 
(ketamine, mephedrone, crystal methamphetamine and 
GBL) will not be affected by the Psychoactive Substances 
Act. We now turn attention to the impact of the Act on the 
availability and use of synthetic cannabinoids. 
From our observations in headshops in Manchester city 
centre, it quickly became clear that the dominant NPS sold 
are synthetic cannabinoids. Over 90 per cent of the sales we 
witnessed were synthetic cannabinoids. Only a very small 
number of purchases of stimulants (such as ‘Gocaine’ and 
‘Ice’n’Berg’) were observed. Similarly, out of the 129 NPS 
packages seized by staff from room searches at an approved 
premises in Manchester, 96 per cent (n=124) were synthetic 
cannabinoids. With this in mind, the remainder of this 
section will focus on the likely impact of the Psychoactive 
Substances Act on the synthetic cannabinoid market 
in Manchester.
The establishment of a LDIS would facilitate the early 
identification, risk assessment and appropriate response 
to NPS, or other drug related trends or concerns (e.g. 
adulterated drugs, bad or strong batches etc.). In section 
3.5.3, we highlighted that interviewees attributed several 
deaths to NPS use, particular synthetic cannabinoid use. The 
systematic approach to information gathering used in the 
LDIS model also has the potential to assist with drug-related 
death reviews (Public Health England, 2016). During the 
course of the research, we encountered significant demand 
and support for a Greater Manchester LDIS. 
‘Yeah, that’d be brilliant, I’d love to be involved with it’. 
(Supported Housing Manager) 
‘I think that would be a very good idea. … You spend all 
your time dealing with it as opposed to thinking “Right, 
hang on, let’s just stop and think who else is affected by 
this. Right, well let’s look at pulling in health, let’s have a 
steering group to collate everything and you know, share 
everything”’. (City Centre Police Officer) 
‘We need an early warning system like Salford have got’. 
(Homeless Day Centre Staff) 
As the above quote alludes to, Salford DAAT have developed 
an Early Warning System (EWS) that provides an information 
sharing protocol for NPS that facilitates the raising of 
awareness to newly identified substances associated with 
local incidents (e.g. non-fatal and fatal intoxication cases 
in the region). The interviews with professionals included 
several very positive accounts from those who were already 
involved in the existing LDIS that has been implemented by 
Mike Linnell and Mark Knight for Salford DAAT. A range of 
stakeholders commented on how the Salford EWS, a pioneer 
model that the recent Public Health England guidance draws 
heavily upon, had helped them to assess local intelligence 
and to issue appropriate public health alerts on new/novel, 
potent, adulterated or contaminated drugs. 
The Salford system has also provided a central location to 
provide specific information on different types of NPS and 
NPS legislation, including an often mentioned simplified 
guide to the recent Psychoactive Substances Act. 
‘One of the good things about the early warning system 
has been that, … when Mike linked in to Drug Watch, as 
he’s been writing stuff for that, that’s been posted on our 
early warning system. And then I know that the medical 
team in treatment service have been using those to brief 
the staff, so I would like to think there’s a high level of 
awareness within our treatment services, because of  
that early warning system’. (Salford DAAT Manager) 
In addition to Salford, during the course of the research 
we became aware that Bury had recently introduced its 
own LDIS whilst a similar review of NPS prevalence and 
provision in Tameside by Liverpool John Moores University 
Centre for Public Health has also recently recommended 
the establishment of a LDIS. With the Greater Manchester 
Devolution on the horizon we therefore recommend (see 
section 4.1) that the establishment of a LDIS is implemented 
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This is not only so dealers can increase their profit margins 
but also to ensure users become increasingly addicted. 
For example, there is already a rumour going around the 
homeless community in Manchester that street level 
synthetic cannabinoids are being mixed with crack cocaine 
to get users addicted. 
‘It’s worse now, because they make it themselves, they 
make it powerful. They’re putting white [crack] with it as 
well’. (Male, mid 20’s, Homeless Day Centre Drop-in)
‘They’re mixing white [crack] in with the Spice so it gets 
you addicted to it, so you keep going back for it more and 
more’. (Female, late 20’s, Homeless Day Centre Drop-in) 
In summary then, the purpose of the Psychoactive Substances 
Act is to shut down all UK-based shops and websites that 
trade in psychoactive substances, with the resulting outcome 
being a reduction in overall availability and subsequent 
use of NPS. While the blanket ban may make purchasing 
NPS harder for occasional recreational NPS users (such as 
young people), for those dependent and entrenched users 
there was clear evidence from this research that the ban 
would have only a limited impact on prevalence rates. For 
example, as soon as the Act came into force on May 26th, 
both users and frontline staff working with the homeless 
community reported clear signs of a flourishing street level 
market for synthetic cannabinoids. Almost immediately, 
dealers appeared on the streets – often close to headshops 
that had previously been well-known sellers of synthetic 
cannabinoids and other NPS – making continued access to 
synthetic cannabinoids easy for users. Nonetheless, there are 
concerns that the incorporation of the synthetic cannabinoid 
market into the illegal street market will have a number 
of negative outcomes, including: an increase in violent 
altercations and robbery amongst homeless users due to 
increased prices and reduced availability; more acquisitive 
crime to fund existing habits; along with the potential for 
additional harms to users as a result of adulteration and/or 
modifications to the chemical structure of these substances. 
This developing synthetic cannabinoid street market clearly 
needs careful monitoring. 
For other NPS user groups, such as students, clubbers and 
men who have sex with men (MSM), many of the popular 
types of NPS they use – such as mephedrone, crystal 
methamphetamine and GHB/GBL – are already established 
on the illegal market, or in the case of nitrous oxide fall 
outside the Act (due to its legitimate use as a food agent). 
As such, it is envisaged that the Psychoactive Substances 
Act will have only a negligible impact on these groups  
of users.
 
In section 3.5, we outlined how 93 per cent of users in 
the Homeless Link Survey reported purchasing synthetic 
cannabinoids from city centre headshops. In addition, 
almost half (45 per cent) stated that the fact that they were 
convenient to purchase as the main reason for use, with 
almost a quarter (24 per cent) stating the fact that they were 
cheaper than other substances as their main reason for use. 
Taking these homeless survey findings into account, it might 
sensibly be assumed that the Psychoactive Substances Act 
will have a tangible impact on the prevalence of synthetic 
cannabinoids. Yet, contrary to this assumption, the homeless 
NPS users that we interviewed confirmed that there was 
an already established street level synthetic cannabinoids 
market in areas of the city centre where NPS users were 
known to congregate (such as around Piccadilly Gardens), 
and they all predicted that this market would increase 
following the implementation of the Act. 
‘It won’t make it harder to get because you’ll just get it off 
the streets’. (Male, mid 20’s, Homeless, City Centre GP 
Surgery Drop-in)
The early indications are that these predictions hold true. 
For example, street dealers are operating close to headshops 
that, as a result of the Act, appear to have stopped selling 
synthetic cannabinoids and other NPS. 
‘You’ve got ten dealers in the [Piccadilly] gardens, just 
sitting there in the gardens’. (Male, mid 20’s, Homeless 
Day Centre Drop-in) 
Added to this, all of the homeless NPS users interviewed 
felt that the Psychoactive Substances Act will simply push 
the synthetic cannabinoids market underground, as was 
found to be the case in Ireland and Poland. Thus potentially 
increasing social and health harms amongst an already 
vulnerable population.
‘It’s not going to go away, … it’s going to go underground, 
to the crime world now’. (30-year old Male, Homeless, City 
Centre GP Surgery Drop-in) 
‘You’re going to push it underground and criminalise it. … 
Instead of scoring crack and heroin, they’re now scoring 
Spice’. (26-year old Male, Supported Housing) 
Since the implementation date for the Act was first mooted 
(originally April 6th 2016), the more entrepreneurial users we 
interviewed talked of planning to take advantage of online 
retailers and headshops promoting bulk purchases or BOGOF 
offers, and of others stockpiling synthetic cannabinoids in 
anticipation for a hike in demand on the street. 
When it comes to availability, we predict that while 
stockpiles last, supply and ultimately usage will continue 
as normal. However, as stocks dwindle and availability 
reduces, we predict that prices will increase. As was the 
case when mephedrone was banned in 2010, prices of 
synthetic cannabinoids have already started to increase 
with users reportedly paying twice as much for street  
deals compared to previous purchases from headshops and 
newsagents/shops.
‘They’ve put it up to a tenner a gram now’. (Female, early 
20’s, Homeless Day Centre Drop-in) 
‘Within a week [of the Act] the prices have already gone 
up’. (Male, mid 20’s, Homeless Day Centre Drop-in)
If, and when, the ban does eventually lead to reduced 
availability, it is likely to impact upon dependent synthetic 
cannabinoids users in a number of key interrelated 
ways. Firstly, it will most likely lead to more incidents 
of robbery and violence amongst users (as outlined in 
section 3.5.6) as they pursue increasingly scarcer supplies 
synthetic cannabinoids.
‘When it gets banned, there’s going to be like groups of 
people, mobs of people getting about. They know you’ve 
got it in your pockets, [and] they’re going to kick your head 
in’. (Male, early 20’s, Homeless, City Centre GP Surgery 
Drop-in)
‘Everyone’s going to be twatting each other’. (18-year old 
Female, Homeless) 
‘It will get a lot, lot worse. People are going to get 
sliced and stabbed up’. (Male, mid 20’s, Homeless Day 
Centre Drop-in) 
Already these predictions seem to have materialised to 
some degree.
‘In town now, they’re all robbing each other, because they 
can’t get it so easily no more’. (Male, mid 20’s, Homeless 
Day Centre Drop-in)
Secondly, a shift from headshops to street level dealing will 
almost certainly lead to poorer quality deals as a street level 
gram can range from 0.5g to 0.8g. This coupled with the price 
hike mentioned above is likely to lead to more acquisitive 
crime being committed to fund regular and dependent use. 
Thirdly, health concerns have been raised in relation to locally 
made synthetic cannabinoids. For example, ‘Annihilation’ 
was widely reported to be made on the premises of a 
Manchester headshop. In contrast to the branded packaging 
associated with NPS purchased in headshops and online, 
this product came in a clear snap-bag with basic labelling. 
During the course of the research, this particular brand 
was repeatedly cited as being more addictive and having 
much more negative effects than other available synthetic 
cannabinoids:
‘That Annihilation stuff is even worse, … absolutely 
disgusting, blows your head off something rotten. 
I wouldn’t even smoke it when I was smoking Spice’. 
(Male, early 20’s, Young people’s homeless drop-in) 
‘I’m addicted to Annihilation, and when I have it, my head 
goes, I don’t know what I’m doing, I don’t know where 
I am. … It’s that strong, I get sick and sweaty and hot 
and cold shivers’. (30-year old Male, Homeless Drop-in, 
Urban Village) 
It is highly likely that street level products are being cut 
with unknown ingredients that may cause further harm. 
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Recommendations
In this final section, we outline a number of recommendations 
that we believe will assist in addressing the issues raised in 
this report. The following recommendations are organised 
into three main themes: 
• The development of resources; 
• Service development; and, 
• Future research agendas. 
These recommendations have been developed in line with the 
good practice prompts outlined in Public Health England’s 
JSNA support pack for 2015-16 (Public Health England, 
2014b), which outlines key principles that local areas should 
reflect upon when developing an integrated alcohol and 
drugs prevention, treatment and recovery system. Whilst we 
endeavored to take on board all of the feedback we received 
from research participants, we acknowledge and are mindful 
of the constraints of the existing public health budget. 
Therefore, the recommendations that follow are based 
around what we believe is tangible within the constraints 
of existing resources and commissioning frameworks as 
opposed to ‘blue sky thinking’. 
4.1 Development of resources 
As we illustrated in section 3.9, the research identified a 
clear need to increase existing NPS-related knowledge 
among specialist substance use providers and a wide 
range of other medical and non-medical occupations 
(ranging from GPs, emergency services staff, supported 
accommodation workers and criminal justice services). 
We propose three main ways of achieving this: the 
development of bespoke information sheets; NPS training 
and continuous professional development (CPDs); and a 
virtual resource to facilitate the sharing of information and 
good practice across services. 
4.1.1 NPS briefing information sheets
The development of brief (i.e. 2-page) information sheets 
targeted at specific services and tailored around the types of 
NPS use they are likely to encounter. For example, synthetic 
cannabinoid information for prisons, offender management 
services, supported housing and approved premises and 
briefing information sheets on the three main substances 
associated with chemsex. 
4.1.2 Drug alerts and local drug 
information system (LDIS) 
In line with section 1.2.4 of Public Health England’s JSNA 
guidance on sharing information with partners about NPS 
through local networks (Public Health England, 2014b), we 
recommend the development of a local drug information 
system (LDIS) and online user and information sharing forum 
similar to the local Salford DAAT model. This would provide 
a centralised, coordinated resource where NPS-related 
intelligence, information and good practice responses can be 
obtained. In January 2016, Public Health England published 
guidance on how to establish local drug information 
systems which we propose should be adhered to (see Public 
Health England, 2016). Within Greater Manchester, similar 
systems have recently been launched (Bury) or proposed 
(Tameside). With Greater Manchester Devolution on the 
horizon, we propose that this initiative is established Greater 
Manchester-wide rather than restricted to Manchester. 
This LDIS would also support the provision of evidence-
based resources and materials for appropriate professionals 
and services, including for example, Public Health England 
NEPTUNE clinical guidelines, European monitoring data and 
academic research reports, together with the aforementioned 
bespoke information sheets and information on local NPS 
training and events. The LDIS would also provide a platform 
for disseminating information on emerging trends, ‘bad 
batches’, good practice and advice on NPS and other emerging 
substance use trends within and between services. The 
resource would not be limited to NPS e.g. it has the capacity 
to cover other emerging drug trends around polydrug use 
and performance and image enhancing drugs (PIEDs). 
We propose that the research team convene a one-day ‘NPS 
awareness day’ that, in addition to reporting on the key 
research findings to invited stakeholders, will act as a launch 
pad for the LDIS. 
4.1.3 NPS training 
We have identified training development need for 
practitioners that moves beyond existing NPS awareness 
training, which tends to be too basic and too broad. This is 
not to dismiss the existing need for training that includes, 
for example: information on definitions; types of NPS; 
popular brand names; drug effects; legislation; potential 
harms; and general harm reduction responses. Rather, we 
advocate that training should also recognise the particular 
issues that different sectors are facing and the knowledge 
gaps that currently exist. For example, interviews with acute 
A&E consultants and nurses identified knowledge gaps and 
competency in relation to the identification of overdose or 
intoxication from synthetic cannabinoids and GBL/GHB. 
While those professionals working in a range of housing 
provision (from care homes to supported accommodation 
and approved premises) highlighted the need for more 
practical information on how to respond to users when they 
are having a bad experience, such as fitting, anxiety attacks 
or respiratory problems. In particular, there was much 
confusion regarding when to call for an ambulance. 
As we outline below in section 4.2, we propose a holistic 
treatment provision for NPS users. This requires staff from 
mental health and substance use services to be trained to 
ensure that they are equipped and feel competent in dealing 
with the mental health and substance use issues that 
commonly co-exist within the user groups we focused on. 
This would minimise the issue identified in section 3.5.5 of 
NPS users being passed back and forth between substance 
use and mental health services. 
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4.2 Service development 
4.2.1 Innovation in service delivery
Our findings suggest the need for more innovation 
in developing intervention responses and marketing 
approaches to encourage service user engagement. There is 
a need for specialised service responses for client groups not 
traditionally accessing drug treatment. This should include, 
where appropriate, a move away from traditional operating 
hours and locations, towards outreach and ‘pop-up’ services. 
For example, ‘pop-up’ needle exchanges to accommodate 
new groups of users (such as crystal methamphetamine and 
PIED users), as well as NPS/club drug clinics and a modified 
outreach/street triage model to target homeless populations. 
Furthermore, a consistent response to the problematic use 
of synthetic cannabinoids may include a community detox 
model and innovation in mental health support. Psychological 
therapy for example, requires engagement and commitment 
from the service user. Often, this is inconsistent with chaotic 
lifestyles and therefore, traditional models of engagement 
may need adaptation to serve the mental health needs of 
homeless populations. In line with the 2015 five-year plan 
for Greater Manchester Combined Authorities (see Warren, 
2016), we propose that the improvements to existing service 
provision, including innovations to delivery models, should 
be developed through the prioritisation of greater efficiency 
coupled with the development of improved communication 
and collaboration across public-sector services.
4.2.2 Models of good practice 
We recommend the establishment of models of good practice 
regarding the treatment of users of synthetic cannabinoids 
and drugs associated with the chemsex scene. This 
should include: advice on synthetic cannabinoids detox; 
appropriateness of prescribing medications (i.e. potential for 
interactions or toxicity with NPS); harm reduction; and if 
and how responses to these types of NPS use may differ to 
traditional substances. This should also include guidance on 
the importance of cultural competency when working with 
specific sub-populations of users (e.g. MSM; hostel clients 
and those at risk of homelessness). 
4.2.3 Improved NPS treatment 
pathways
The lack of clarity around referral pathways we identified 
in section 3.8 necessitates a review of existing partnership 
working, to ensure better care pathways and the facilitation 
of inter-agency communication between mental health and 
substance misuse services and, in the case of chemsex users, 
sexual health services. In section 3.8.4 we highlighted how 
the Dual Diagnosis Liaison Service and CGL have conducted 
a review of dual diagnosis pathways. This comprises 
the development of revised guidance on impatient Dual 
Diagnosis Referrals to the Manchester integrated alcohol and 
drug service. Whilst this is clearly a positive development, 
we suggest that this should include the establishment of 
clear NPS treatment pathways that are developed through 
effective working alliances and collaborative partnerships 
with emergency services, criminal justice agencies, housing 
providers, and third sector organisations (e.g. Lifeshare; 
Booth Centre; LGBT Foundation, COR, Homeless Link), 
thus facilitating clear referral routes and shared learning. 
This should also include better marketing of what services 
currently offer when supporting specific NPS users. The 
recently updated 2016 NICE guidance on coexisting severe 
mental illness and substance misuse (NICE 2016, see in 
particular section 1.4) provides timely best practice advice 
on partnership working between specialist services, health, 
social care and other support services and commissioners.
In section 3.5.6, we outlined a range of crimes linked to 
the use of synthetic cannabinoids, yet because these drugs 
are not detected by existing drug tests targeted at users 
of opioids and (crack) cocaine, these users are not likely to 
be referred to appropriate services via the criminal justice 
system. In consideration of section 1.5 of current Public 
Health England JSNA guidance (Public Health England, 
2014b), we propose a review of existing criminal justice 
pathways into treatment for users of synthetic cannabinoids 
and other NPS. Furthermore, we suggest engagement 
with local Offender Management Services and community 
rehabilitation organisations to develop appropriate 
interventions for offenders subject to statutory supervision 
in the community or on release from prison. 
4.2.4 Integrated service delivery 
Over the last two years, the Mental Health Improvement 
Programme (MHIP) has undertaken a wide range of 
public engagement activity to inform plans to improve 
mental health services across the city. The Mental Health 
Improvement Programme has acknowledged that having 
a number of different organisations contracted separately 
to provide mental health services in Manchester has led 
to fragmentation and a lack of joined-up care. A central 
aim of the programme is to create a better system in the 
future that provides co-ordinated care to individuals with 
mental health support needs. The evidence presented in 
this report adds support for the need for the improvement 
programme. Section 5.14 of the Public Health England JSNA 
guidance (Public Health England, 2014b) highlights the 
need for protocols and pathways to support service users 
who have both alcohol and drug misuse and mental health 
problems, including those in crisis. A key theme arising from 
the findings was the challenge of managing clients with 
complex needs, in particular, dual diagnosis, and providing 
appropriate and effective support around their use of NPS. 
A broad spectrum of professionals were keen to stress 
that it is imperative service users with co-existing mental 
health and substance use problems are viewed and treated 
holistically. Despite the existence of a dual diagnosis team 
and dedicated support for young people with mental health 
issues, there was evidence of a need for more integration of 
substance use and mental health for NPS users (see sections 
3.4.7, 3.5.4, 3.5.5 and 3.8.4). The findings present clear 
evidence of a need for improved clinical and psychosocial 
responses regarding the use of NPS, in particular, synthetic 
cannabinoids amongst vulnerable groups (young people, 
homeless and offender populations) to address the range 
of mental health issues attributed to the consumption of 
synthetic cannabinoids. The issues regarding access that 
have been identified are beginning to be addressed as part 
of the Mental Health Improvement Programme that includes 
service integration and the recent recommissioning of 
integrated alcohol and drug and mental health services. The 
recent announcement that Greater Manchester West Mental 
Health NHS Foundation Trust will take responsibility for 
Manchester Mental Health and Social Care Trust services 
from January 2017 provides a timely opportunity for these 
concerns to be addressed. 
The establishment of the REACH clinic to address the 
emergent chemsex scene provides one example of existing 
good practice, innovation and integrated service delivery. 
Our findings suggest that continued collaboration between 
key services should be encouraged and supported, 
incorporating a wider range of services and organisations 
that come into contact with users, or potential users, of NPS. 
In relation to the REACH clinic, as we outlined in section 3.4, 
there is scope for expansion and development of the service 
to incorporate mental, as well as sexual health services, 
and to expand to the three other sexual health centres in 
Manchester. An expansion of opening hours and a focus 
on developing partnership working and clear pathways is 
necessary to further increase engagement with the much 
larger numbers of users estimated to be involved in chemsex 
in the region. The recent establishment (1st July 2016) of 
a single integrated sexual health service for Manchester 
provides an ideal opportunity to review how support for 
people who engage in chemsex is provided and to develop 
referral pathways e.g. from spoke clinics.
4.2.5 NPS user engagement strategy
The Public Health England JSNA guidance on needs 
assessment (see section 1.2, Public Health England, 2014b) 
highlights the requirement to establish the levels of drug 
treatment penetration by dependent users. In section 3.5, 
we noted that there is a sub-population who describe their 
consumption of synthetic cannabinoids as ‘dependent’ or 
‘addictive’, yet they are not engaging with services. As 
we outlined in section 3.8, in addition to establishing clear 
referral pathways, there is a need for clear information and 
signposting about what substance use services can offer 
NPS users. It is essential to develop a local communication 
campaign to dispel NPS misconceptions and design targeted 
campaigns to encourage service uptake among high-risk 
groups (i.e. the homeless, offenders and MSM engaged 
in chemsex).
These should be developed in tandem with a strategy that 
recognises that the lack of engagement with drug services 
by NPS users is often due to the services’ perceived client 
group, location, stigma, and what intervention they can offer. 
How this might be addressed needs further consultation. We 
propose a number of models, including a more integrated 
centralised service allowing users to access a range of 
services without being labelled as ‘drug users’. As we 
highlighted in section 3.4, there are several London-based 
examples of good practice that could be drawn on, such as 
the ‘Club Drug Clinic’ developed by the Central and North 
West London NHS Foundation Trust which incorporates the 
needs of chemsex users, but also the wider LGBT, student 
and clubbing populations. 
4.3 Future research agendas 
4.3.1 Developing monitoring and 
recording systems 
The research uncovered much higher levels of (problematic) 
use of NPS – especially synthetic cannabinoid use – than 
existing data sources currently demonstrate. In section 
3.6, we highlighted how NPS use has considerable impact 
on a number of services including: city centre police; the 
ambulance service; A&E departments; GPs; sexual health 
clinics; supported accommodation providers; offender 
management services (especially approved premises); and 
the prison service. However, recording of NPS use and 
incidents is inconsistent and patchy. A review of existing 
data sources and monitoring tools used by all agencies 
working with NPS users is recommended to improve existing 
systems, and in particular, to develop codes for recording 
NPS incidents more accurately. 
4.3.2 The impact of NPS use on 
recovery journeys
Building recovery is central to all drug and alcohol strategies 
at a local and national level. In section 3.5 we noted how 
many synthetic cannabinoid users reported being ‘ex-heroin 
addicts’ or dependent on other drugs and/or alcohol. They 
often discussed past engagement with treatment services. 
However, despite disclosing a range of mental and physical 
health problems and perceived addiction to synthetic 
cannabinoids, they were no longer accessing treatment 
services. Further exploration is necessary to establish the 
impact that some types of NPS use are having on recovery 
journeys – both in custodial settings and the community. 
For example, are people who might previously have become 
abstinent now switching to NPS use instead? It is important 
that services highlight the potential harms that NPS use can 
lead to and are aware of the potential that NPS use can have 
on individuals’ recovery journeys. 
4.3.3 The impact of NPS use on 
crime and disorder and offender 
management
The research uncovered that many of the more problematic 
users of NPS were first introduced to it in custodial settings 
(adult prison or young offender institutes) and many were 
using NPS to avoid MDTs in emergency housing, supported 
housing and approved premises, or to comply with their 
offender management license conditions. It was evident 
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that continued use beyond the prison estate was causing 
problems for offender management, approved premises 
and other forms of supported housing provision in the 
city. We therefore propose the need to further consider the 
impact of NPS use is having in custody (including within 
the female secure estate) and on release in the community, 
for example, in approved premises, supported housing or 
hostels. In particular, what impact do MDTs and other 
license conditions have on motivations for use? 
We suggest further research is required to explore the role 
of the prison system and the impact of NPS use amongst 
the offending population that where possible, includes local 
prisons (e.g. Forest Bank, HMP Manchester and HMP Styal) 
and the Greater Manchester Probation Service and Youth 
Offending Teams. We also propose further exploration of 
the links between NPS addiction/dependency and offending 
behaviours to fund use. This should also explore the 
relationship between NPS use, violence and victimisation. 
4.3.4 Monitoring of the impact of the 
Psychoactive Substances Act 2016
As we reported in section 3.11, the evidence suggests that it 
is highly probable that the change in legislation that occurred 
on the 26th May 2016 to prohibit the sale of NPS will result 
in some of the more popular types of NPS being sold on the 
illegal drugs market. Monitoring of this situation, including 
test purchasing and analysis is important in gaining 
information on what specific compounds are potentially 
being purchased and used locally. 
4.3.5 Continued monitoring of 
emerging drug trends and markets
The Public Health England JSNA guidance (Public Health 
England, 2014b) emphasises the need to plan according to 
local needs assessments. This includes an understanding of 
local demands and needs obtained through a combination 
of local and national data. As we illustrated in sections 3.1 
to 3.5, many NPS users are not engaged with services. 
Moreover, in section 3.7, we highlighted a range of existing 
limitations with data collection. We therefore propose the 
establishment of an annual (Greater) Manchester ‘Street Drug 
Survey’ that captures data from specific sub-populations 
such as prisoners, the homeless, clubbers, students, and 
the LGBT community, alongside the insight of professionals 
in regular contact with a range of substance users. A survey 
of this nature would facilitate the early identification of new 
and emerging trends (e.g. performance and image enhancing 
drugs, ‘smart drugs’, or abuse of prescribed drugs), alongside 
existing substance use, such as NPS. An annual survey of 
this nature would be invaluable in terms of informing service 
development and commissioning services, thus helping to 
ensure a more comprehensive and appropriate provision of 
services in (Greater) Manchester.
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